Tumors or cancer of the PERITONEUM.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Neoplasms containing cyst-like formations or producing mucin or serum.
Tumors or cancer of the SKIN.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Tumors or cancers of the KIDNEY.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Tumors or cancer of the THYROID GLAND.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
DNA present in neoplastic tissue.
Tumors or cancer of the LUNG.
Tumors or cancer of the PAROTID GLAND.
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.
Tumors or cancer of the APPENDIX.
Tumors or cancer of the LIVER.
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Tumors or cancer of the ENDOCRINE GLANDS.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.
Tumors or cancer of the EYE.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Tumors or cancer of the NOSE.
Tumors or cancer of the SALIVARY GLANDS.
Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
A benign epithelial tumor with a glandular organization.
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Tumors or cancer of the UTERUS.
Tumors or cancer of the INTESTINES.
Neoplasms composed of sebaceous or sweat gland tissue or tissue of other skin appendages. The concept does not refer to neoplasms located in the sebaceous or sweat glands or in the other skin appendages.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.
Sweat gland neoplasms are abnormal growths that can be benign or malignant, originating from the sweat glands (eccrine or apocrine) and found anywhere on the skin surface.
A general term for various neoplastic diseases of the lymphoid tissue.
Tumors or cancer located in bone tissue or specific BONES.
Tumors or cancer of the PALATE, including those of the hard palate, soft palate and UVULA.
Neoplasms composed of more than one type of neoplastic tissue.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Tumors or cancer of the MANDIBLE.
A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
Tumors or cancer of the BILE DUCTS.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
Tumors or cancer of the THYMUS GLAND.
Tumors or cancer of the SPLEEN.
Tumors in any part of the heart. They include primary cardiac tumors and metastatic tumors to the heart. Their interference with normal cardiac functions can cause a wide variety of symptoms including HEART FAILURE; CARDIAC ARRHYTHMIAS; or EMBOLISM.
A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)
Tumors or cancer of the COLON.
Cancer or tumors of the MAXILLA or upper jaw.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.
Tumors or cancer of the anal gland.
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.
Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.
Neoplasms composed of fatty tissue or connective tissue made up of fat cells in a meshwork of areolar tissue. The concept does not refer to neoplasms located in adipose tissue.
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.
Tumors or cancer of the DUODENUM.
Tumors or cancers of the ADRENAL CORTEX.
Tumors or cancer of the MOUTH.
Tumors or cancer of the MEDIASTINUM.
Tumors or cancer of the TONGUE.
Tumors or cancer in the ILEUM region of the small intestine (INTESTINE, SMALL).
Tumors or cancer of the STOMACH.
Tumors or cancer of the URINARY BLADDER.
A malignant tumor arising from secreting cells of a racemose gland, particularly the salivary glands. Racemose (Latin racemosus, full of clusters) refers, as does acinar (Latin acinus, grape), to small saclike dilatations in various glands. Acinar cell carcinomas are usually well differentiated and account for about 13% of the cancers arising in the parotid gland. Lymph node metastasis occurs in about 16% of cases. Local recurrences and distant metastases many years after treatment are common. This tumor appears in all age groups and is most common in women. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1240; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575)
Benign and malignant neoplasms which occur within the substance of the spinal cord (intramedullary neoplasms) or in the space between the dura and spinal cord (intradural extramedullary neoplasms). The majority of intramedullary spinal tumors are primary CNS neoplasms including ASTROCYTOMA; EPENDYMOMA; and LIPOMA. Intramedullary neoplasms are often associated with SYRINGOMYELIA. The most frequent histologic types of intradural-extramedullary tumors are MENINGIOMA and NEUROFIBROMA.
Tumors or cancer of the VAGINA.
A usually benign glandular tumor composed of oxyphil cells, large cells with small irregular nuclei and dense acidophilic granules due to the presence of abundant MITOCHONDRIA. Oxyphil cells, also known as oncocytes, are found in oncocytomas of the kidney, salivary glands, and endocrine glands. In the thyroid gland, oxyphil cells are known as Hurthle cells and Askanazy cells.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Benign and malignant neoplastic processes arising from or involving components of the central, peripheral, and autonomic nervous systems, cranial nerves, and meninges. Included in this category are primary and metastatic nervous system neoplasms.
A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tumors or cancer located in muscle tissue or specific muscles. They are differentiated from NEOPLASMS, MUSCLE TISSUE which are neoplasms composed of skeletal, cardiac, or smooth muscle tissue, such as MYOSARCOMA or LEIOMYOMA.
Experimentally induced tumors of the LIVER.
A rare malignant neoplasm characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood vessels and lining irregular blood-filled or lumpy spaces. (Stedman, 25th ed)
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
A malignant epithelial tumor with a glandular organization.
Clonal myeloid disorders that possess both dysplastic and proliferative features but are not properly classified as either MYELODYSPLASTIC SYNDROMES or MYELOPROLIFERATIVE DISORDERS.
Surgical removal of the pancreas. (Dorland, 28th ed)
Neoplasms which arise from peripheral nerve tissue. This includes NEUROFIBROMAS; SCHWANNOMAS; GRANULAR CELL TUMORS; and malignant peripheral NERVE SHEATH NEOPLASMS. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp1750-1)
Neoplasms located in the brain ventricles, including the two lateral, the third, and the fourth ventricle. Ventricular tumors may be primary (e.g., CHOROID PLEXUS NEOPLASMS and GLIOMA, SUBEPENDYMAL), metastasize from distant organs, or occur as extensions of locally invasive tumors from adjacent brain structures.
Tumors or cancer of the PARANASAL SINUSES.
Neoplasms of the thin serous membrane that envelopes the lungs and lines the thoracic cavity. Pleural neoplasms are exceedingly rare and are usually not diagnosed until they are advanced because in the early stages they produce no symptoms.
Tumors or cancer of the human BREAST.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Tumor or cancer of the COMMON BILE DUCT including the AMPULLA OF VATER and the SPHINCTER OF ODDI.
Neoplasms of the bony orbit and contents except the eyeball.
Abdominal neoplasms refer to abnormal growths or tumors occurring within the abdominal cavity, which can be benign or malignant, and affect various organs such as the pancreas, liver, kidneys, or intestines.
Primary or metastatic neoplasms of the CEREBELLUM. Tumors in this location frequently present with ATAXIA or signs of INTRACRANIAL HYPERTENSION due to obstruction of the fourth ventricle. Common primary cerebellar tumors include fibrillary ASTROCYTOMA and cerebellar HEMANGIOBLASTOMA. The cerebellum is a relatively common site for tumor metastases from the lung, breast, and other distant organs. (From Okazaki & Scheithauer, Atlas of Neuropathology, 1988, p86 and p141)
A benign tumor composed of fat cells (ADIPOCYTES). It can be surrounded by a thin layer of connective tissue (encapsulated), or diffuse without the capsule.
Facial neoplasms are abnormal growths or tumors that develop in the facial region, which can be benign or malignant, originating from various cell types including epithelial, glandular, connective tissue, and neural crest cells.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
A collective term for precoordinated organ/neoplasm headings locating neoplasms by organ, as BRAIN NEOPLASMS; DUODENAL NEOPLASMS; LIVER NEOPLASMS; etc.
Tumors or cancer of the BRONCHI.
Distinctive neoplastic disorders of histiocytes. Included are malignant neoplasms of MACROPHAGES and DENDRITIC CELLS.
Tumors or cancer of the UROGENITAL SYSTEM in either the male or the female.
Spinal neoplasms are abnormal growths or tumors that develop within the spinal column, which can be benign or malignant, and originate from cells within the spinal structure or spread to the spine from other parts of the body (metastatic).
Neoplasms of the bony part of the skull.
Tumors or cancer of the VULVA.
Neoplasms composed of neuroepithelial cells, which have the capacity to differentiate into NEURONS, oligodendrocytes, and ASTROCYTES. The majority of craniospinal tumors are of neuroepithelial origin. (From Dev Biol 1998 Aug 1;200(1):1-5)
Tumors or cancer of any part of the hearing and equilibrium system of the body (the EXTERNAL EAR, the MIDDLE EAR, and the INNER EAR).
Tumors or cancer of the LIP.
A benign tumor of fibrous or fully developed connective tissue.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Tumors or cancer of the ADRENAL GLANDS.
Tumors or cancer of the pelvic region.
'Gingival neoplasms' are abnormal, uncontrolled growths of tissue originating from the gingiva, which can be benign (non-cancerous) or malignant (cancerous), often manifesting as swellings, ulcerations, or masses within the oral cavity.
Tumors or cancer of the gallbladder.
The local implantation of tumor cells by contamination of instruments and surgical equipment during and after surgical resection, resulting in local growth of the cells and tumor formation.
Neoplasms composed of fibrous and epithelial tissue. The concept does not refer to neoplasms located in fibrous tissue or epithelium.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Respiratory Tract Neoplasms are defined as abnormal growths or tumors that develop within the respiratory system, including the nose, sinuses, throat (pharynx), voice box (larynx), windpipe (trachea), bronchi, and lungs, which can be benign or malignant, with the potential to cause significant morbidity and mortality.
Neoplasms composed of connective tissue, including elastic, mucous, reticular, osseous, and cartilaginous tissue. The concept does not refer to neoplasms located in connective tissue.
Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.

Laparoscopic staging of gastric cancer is safe and affects treatment strategy. (1/1217)

The accuracy of laparoscopic staging has been documented, but its safety and impact on clinical decision making are less clear. In a prospective series of 64 patients referred to a single consultant, laparoscopy was performed in 49, after exclusion of patients unlikely to derive benefit from laparoscopic staging. The prelaparoscopy treatment plan was altered in 17 (34%). Laparoscopy detected 11 cases of peritoneal and four cases of liver metastasis, of which nine and two, respectively, were not detected by CT scan. Laparoscopy was useful in assessing fitness for major surgery, the planned extent of which was reduced in five cases as a result. Port site metastasis occurred in one case of stage IVB cancer, in conjunction with widespread progressive disease. Laparoscopic staging is recommended in gastric cancer, since it causes important changes to the management plan in one-third of cases, and the risks of port site metastasis appear low.  (+info)

Signet ring cell carcinoma of the stomach: a clinicopathological comparison with the other histological types. (2/1217)

A retrospective analysis was carried out on 93 patients with signet ring cell carcinoma of the stomach operated on between 1985 and 1995, to review the clinicopathologic characteristics from the database of gastric cancer at Sendai National Hospital. The results were compared with those for 590 patients with other types of gastric carcinoma. Women were afflicted as commonly as men in the signet ring cell carcinoma group. These patients tended to be younger and to have larger tumors. The histological type was commonly scirrhous and infiltrative. The survival of patients with signet ring cell carcinoma was worse than that of patients with other types of gastric cancer but the difference was not statistically significant. Patients with early signet ring cell carcinoma had a good prognosis, similar to that of the other groups. However, prognosis of patients with advanced signet ring cell carcinoma was poor compared with patients with other types of this disease. In multivariate analysis, the statistical significant prognostic factors were vascular microinvasion and tumor location. These findings suggest that signet ring cell carcinoma of the stomach should be regarded as a distinct type of gastric cancer.  (+info)

Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. (3/1217)

Oxamflatin [(2E)-5-[3-[(phenylsufonyl) aminol phenyl]-pent-2-en-4-ynohydroxamic acid] induces transcriptional activation of junD and morphological reversion in various NIH3T3-derived transformed cell lines. We found that oxamflatin showed in vitro antiproliferative activity against various mouse and human tumor cell lines with drastic changes in the cell morphology and in vivo antitumor activity against B16 melanoma. Oxamflatin caused an elongated cell shape with filamentous protrusions as well as arrest of the cell cycle at the G1 phase in HeLa cells. These phenotypic changes of HeLa cells were apparently similar to those by trichostatin A (TSA), a specific inhibitor of histone deacetylase (HDAC). The effect of oxamflatin on the transcriptional activity of the cytomegalovirus (CMV) promoter was examined and compared with known HDAC inhibitors, TSA, sodium n-butyrate, and FR901228. Oxamflatin as well as all these inhibitors greatly enhanced the transcriptional activity of the CMV promoter in a dose-dependent manner. Oxamflatin, like TSA, inhibited intracellular HDAC activity, as a result of which marked amounts of acetylated histone species accumulated. Finally, effects on expression of several endogenous genes involved in cell morphology and cell cycle control in HeLa cells were analysed. Expression of gelsolin, cyclin E and Cdk inhibitors including p21WAF1/Cip1 was highly augmented, while that of cyclin A and cyclin D1 was decreased by oxamflatin. These results suggest that changes in the expression pattern of the genes regulating cell morphology and the cell cycle due to histone hyperacetylation are responsible for the antitumor activity, the morphological change and the cell cycle arrest induced by oxamflatin.  (+info)

Asbestos related mortality in Northern Ireland: 1985-1994. (4/1217)

BACKGROUND: The association between Belfast and research into the hazardous effects of asbestos exposure goes back many years. This paper aims to update previous papers and review the burden of asbestos related disease in Northern Ireland today. METHODS: A study was carried out of all deaths in Northern Ireland between 1985 and 1994 inclusive, in which an asbestos related disease was mentioned anywhere on the death certificate. RESULTS: During this 10 year period, 527 asbestos related deaths were recorded; 88 per cent of these were in men. A total of 410 (77.8 per cent) were registered as the primary cause of death but only 405 (76.9 per cent) of cases were the subject of an autopsy. Standardized rates of pleural cancer in males have been increasing at 3.2 per cent per year though the trend was not significant. Lower rates in the last two years may herald the commencement of a decline. Deaths were clustered around the Belfast estuary, the site of Northern Ireland's shipbuilding industry. High proportional mortality ratios were demonstrated for occupations associated with the shipbuilding and construction industries. Evidence is presented that casts doubt on the attribution of peritoneal cancers in females to asbestos exposure. If lung cancers are included, there may be an average of 81 asbestos related deaths in Northern Ireland every year. CONCLUSION: Asbestos related diseases continue to extract a heavy burden of ill health in Northern Ireland today. There are some indications that the upward trend may be on the wane but confirmation of this will have to await further data. Measures to reduce exposure in the workplace to both asbestos and to tobacco smoke are the only means of reducing this burden.  (+info)

Repeated cycles of retrovirus-mediated HSVtk gene transfer plus ganciclovir increase survival of rats with peritoneal carcinomatosis. (5/1217)

Peritoneal carcinomatosis is a common clinical situation that requires novel therapeutic approaches. We investigated the efficiency of an HSVtk gene therapy for the treatment of peritoneal carcinomatosis induced in syngeneic rats by DHD/K12 colon carcinoma cells. In this setting, the efficiency of two different retrovirus producing cell lines (GP+AmEnv12 and FLYA13) was compared. Rats treated with a single injection of retrovirus producing cells followed by a 5-day course of ganciclovir treatment showed an increased survival as compared with control animals. Animals treated with three injections of producing cells, each followed by a 4-5-day course of ganciclovir treatment, showed an increased survival as compared with control rats and with those treated with a single cycle of retrovirus producing cells plus ganciclovir. However, only a few animals remained tumor-free after day 180. There was no difference between the two producing cell lines in any of the experiments. RT-PCR demonstrated a faint expression of the tk transgene in the liver, spleen, epiploon, bowels and the lung of the animals injected with the HSVtk producing cells, reflecting most likely the transduction of only a limited number of cells.  (+info)

Immunohistochemical analysis of PAI-2 (plasminogen activator inhibitor type 2) and p53 protein in early gastric cancer patients with recurrence: a preliminary report. (6/1217)

BACKGROUND: High levels of urokinase-type plasminogen activator (u-PA) were demonstrated in gastric carcinomas along with inhibitors of plasminogen activators (PAI-1 and PAI-2). They may influence the ability to invade and metastasize and therefore be of importance to the risk of recurrence of stomach neoplasms after curative operation. This also appears to be the case for p53 mutations and p53 protein overexpression. METHODS: Six patients, all differentiated cancer cases who developed recurrent disease 5-10 years after curative operations for early gastric cancers (recurrence group), were studied in comparison with 49 patients who had no recurrence more than 10 years after similar surgery (control group). The expression of u-PA, PAI-1, PAI-2 and p53 was compared immunohistochemically in the recurrence and control groups. RESULTS: The expression of PAI-2 was significantly more frequent in the recurrence group, being found in five (83.3%) patients vs eight (16.3%) in the control group. p53 was expressed in five (83.3%) patients in the recurrence group and in 15 (30.6%) in the control group; the rate was again significantly higher in the former. CONCLUSION: The results suggest that PAI-2 and p53 expressed in differentiated early gastric cancers are possible indices of the risk of recurrence.  (+info)

Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity. (7/1217)

The tumor-associated glycoprotein 72 (TAG-72) antigen is present on a high percentage of tumor types including ovarian carcinomas. Antibody B72.3 is a murine monoclonal recognizing the surface domain of the TAG-72 antigen and has been widely used in human clinical trials. After our initial encouraging studies (M. G. Rosenblum et al., J. Natl. Cancer Inst., 83: 1629-1636, 1991) of tissue disposition, metabolism, and pharmacokinetics in 9 patients with ovarian cancer, we designed an escalating dose, multi-arm Phase I study of 90Y-labeled B72.3 i.p. administration. In the first arm of the study, patients (3 pts/dose level) received an i.p. infusion of either 2 or 10 mg of B72.3 labeled with either 1, 10, 15, or 25 mCi of 90Y. Pharmacokinetic studies demonstrated that concentrations of 90Y-labeled B72.3 persist in peritoneal fluid with half-lives >24 h after i.p. administration. In addition, 90Y-labeled B72.3 was absorbed rapidly into the plasma with peak levels achieved within 48 h, and levels declined slowly thereafter. Cumulative urinary excretion of the 90Y label was 10-20% of the administered dose which suggests significant whole-body retention of the radiolabel. Biopsy specimens of bone and marrow obtained at 72 h after administration demonstrated significant content of the label in bone (0.015% of the dose/g) with relatively little in marrow (0.005% of the dose/g). The maximal tolerated dose was determined to be 10 mCi because of hematological toxicity and platelet suppression. This typically occurred on the 29th day after administration and was thought to be a consequence of the irradiation of the marrow from the bony deposition of the radiolabel. In an effort to suppress the bone uptake of 90Y, patients were treated with a continuous i.v. infusion of EDTA (25 mg/kg/12 h x 6) infused immediately before i.p. administration of the radiolabeled antibody. Patients (3 pts/dose level) were treated with doses of 10, 15, 20, 25, 30, 35, 40, or 45 mCi of 90Y-labeled B72.3 for a total of 38 patients. EDTA administration resulted in significant myeloprotection, which allowed escalation to the maximal tolerated dose of 40 mCi. Dose-limiting toxicity was thrombocytopenia and neutropenia. Studies of plasma and peritoneal fluid pharmacokinetics demonstrate no changes compared with patients without EDTA pretreatment. Cumulative urinary excretion of the radiolabel was not increased in patients pretreated with EDTA compared with the untreated group. However, analysis of biopsy specimens of bone and marrow demonstrated that bone and marrow content of the 90Y label was 15-fold lower (<0.001% injected dose/g) than a companion group without EDTA. Four responses were noted in patients who received 15-30 mCi of 90Y-labeled B72.3 with response durations of 1-12 months. These results demonstrate the myeloprotective ability of EDTA, which allows safe i.p. administration of higher doses of 90Y-labeled B72.3 and, therefore, clearly warrant an expanded Phase II trial in patients with minimal residual disease after standard chemotherapy or for the palliation of refractory ascites.  (+info)

Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival. (8/1217)

Most ovarian carcinomas present at advanced stage, principally as the result of dissemination to peritoneal sites. Standard CD44 (CD44S) is the principal receptor for hyaluronic acid, and in vitro and animal studies have suggested that the attachment of ovarian carcinoma cells to the peritoneal mesothelium involves the interaction between CD44S on ovarian carcinoma cells and hyaluronic acid on mesothelial surfaces. We, therefore, analyzed a series of ovarian carcinomas for the expression of CD44S by immunohistochemistry to see whether expression of this receptor by tumor cells correlated with clinicopathological factors and measures of patient outcome. Fifty-six fixed, paraffin-embedded primary epithelial ovarian tumors were immunostained with antibody to CD44S. Membrane staining was considered positive, and results were correlated with stage, grade, age, histology, and survival. Twenty-two (39%) tumors were positive for CD44S. There was no correlation between CD44 expression and histological type, grade, age, or stage. However, CD44 expression was significantly associated with survival in both univariate (P = 0.003) and multivariate (P = 0.006) analyses. These results support a role for CD44S expression in the spread of ovarian epithelial cancer and suggest that expression of this molecule is a significant independent predictor of survival in women with this disease.  (+info)

Peritoneal neoplasms refer to tumors or cancerous growths that develop in the peritoneum, which is the thin, transparent membrane that lines the inner wall of the abdomen and covers the organs within it. These neoplasms can be benign (non-cancerous) or malignant (cancerous). Malignant peritoneal neoplasms are often associated with advanced stages of gastrointestinal, ovarian, or uterine cancers and can spread (metastasize) to other parts of the abdomen.

Peritoneal neoplasms can cause various symptoms such as abdominal pain, bloating, nausea, vomiting, loss of appetite, and weight loss. Diagnosis typically involves imaging tests like CT scans or MRIs, followed by a biopsy to confirm the presence of cancerous cells. Treatment options may include surgery, chemotherapy, radiation therapy, or a combination of these approaches, depending on the type, stage, and location of the neoplasm.

Pancreatic neoplasms refer to abnormal growths in the pancreas that can be benign or malignant. The pancreas is a gland located behind the stomach that produces hormones and digestive enzymes. Pancreatic neoplasms can interfere with the normal functioning of the pancreas, leading to various health complications.

Benign pancreatic neoplasms are non-cancerous growths that do not spread to other parts of the body. They are usually removed through surgery to prevent any potential complications, such as blocking the bile duct or causing pain.

Malignant pancreatic neoplasms, also known as pancreatic cancer, are cancerous growths that can invade and destroy surrounding tissues and organs. They can also spread (metastasize) to other parts of the body, such as the liver, lungs, or bones. Pancreatic cancer is often aggressive and difficult to treat, with a poor prognosis.

There are several types of pancreatic neoplasms, including adenocarcinomas, neuroendocrine tumors, solid pseudopapillary neoplasms, and cystic neoplasms. The specific type of neoplasm is determined through various diagnostic tests, such as imaging studies, biopsies, and blood tests. Treatment options depend on the type, stage, and location of the neoplasm, as well as the patient's overall health and preferences.

Neoplasms are abnormal growths of cells or tissues in the body that serve no physiological function. They can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow growing and do not spread to other parts of the body, while malignant neoplasms are aggressive, invasive, and can metastasize to distant sites.

Neoplasms occur when there is a dysregulation in the normal process of cell division and differentiation, leading to uncontrolled growth and accumulation of cells. This can result from genetic mutations or other factors such as viral infections, environmental exposures, or hormonal imbalances.

Neoplasms can develop in any organ or tissue of the body and can cause various symptoms depending on their size, location, and type. Treatment options for neoplasms include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy, among others.

Neoplasms: Neoplasms refer to abnormal growths of tissue that can be benign (non-cancerous) or malignant (cancerous). They occur when the normal control mechanisms that regulate cell growth and division are disrupted, leading to uncontrolled cell proliferation.

Cystic Neoplasms: Cystic neoplasms are tumors that contain fluid-filled sacs or cysts. These tumors can be benign or malignant and can occur in various organs of the body, including the pancreas, ovary, and liver.

Mucinous Neoplasms: Mucinous neoplasms are a type of cystic neoplasm that is characterized by the production of mucin, a gel-like substance produced by certain types of cells. These tumors can occur in various organs, including the ovary, pancreas, and colon. Mucinous neoplasms can be benign or malignant, and malignant forms are often aggressive and have a poor prognosis.

Serous Neoplasms: Serous neoplasms are another type of cystic neoplasm that is characterized by the production of serous fluid, which is a thin, watery fluid. These tumors commonly occur in the ovary and can be benign or malignant. Malignant serous neoplasms are often aggressive and have a poor prognosis.

In summary, neoplasms refer to abnormal tissue growths that can be benign or malignant. Cystic neoplasms contain fluid-filled sacs and can occur in various organs of the body. Mucinous neoplasms produce a gel-like substance called mucin and can also occur in various organs, while serous neoplasms produce thin, watery fluid and commonly occur in the ovary. Both mucinous and serous neoplasms can be benign or malignant, with malignant forms often being aggressive and having a poor prognosis.

Skin neoplasms refer to abnormal growths or tumors in the skin that can be benign (non-cancerous) or malignant (cancerous). They result from uncontrolled multiplication of skin cells, which can form various types of lesions. These growths may appear as lumps, bumps, sores, patches, or discolored areas on the skin.

Benign skin neoplasms include conditions such as moles, warts, and seborrheic keratoses, while malignant skin neoplasms are primarily classified into melanoma, squamous cell carcinoma, and basal cell carcinoma. These three types of cancerous skin growths are collectively known as non-melanoma skin cancers (NMSCs). Melanoma is the most aggressive and dangerous form of skin cancer, while NMSCs tend to be less invasive but more common.

It's essential to monitor any changes in existing skin lesions or the appearance of new growths and consult a healthcare professional for proper evaluation and treatment if needed.

Multiple primary neoplasms refer to the occurrence of more than one primary malignant tumor in an individual, where each tumor is unrelated to the other and originates from separate cells or organs. This differs from metastatic cancer, where a single malignancy spreads to multiple sites in the body. Multiple primary neoplasms can be synchronous (occurring at the same time) or metachronous (occurring at different times). The risk of developing multiple primary neoplasms increases with age and is associated with certain genetic predispositions, environmental factors, and lifestyle choices such as smoking and alcohol consumption.

Kidney neoplasms refer to abnormal growths or tumors in the kidney tissues that can be benign (non-cancerous) or malignant (cancerous). These growths can originate from various types of kidney cells, including the renal tubules, glomeruli, and the renal pelvis.

Malignant kidney neoplasms are also known as kidney cancers, with renal cell carcinoma being the most common type. Benign kidney neoplasms include renal adenomas, oncocytomas, and angiomyolipomas. While benign neoplasms are generally not life-threatening, they can still cause problems if they grow large enough to compromise kidney function or if they undergo malignant transformation.

Early detection and appropriate management of kidney neoplasms are crucial for improving patient outcomes and overall prognosis. Regular medical check-ups, imaging studies, and urinalysis can help in the early identification of these growths, allowing for timely intervention and treatment.

A "second primary neoplasm" is a distinct, new cancer or malignancy that develops in a person who has already had a previous cancer. It is not a recurrence or metastasis of the original tumor, but rather an independent cancer that arises in a different location or organ system. The development of second primary neoplasms can be influenced by various factors such as genetic predisposition, environmental exposures, and previous treatments like chemotherapy or radiation therapy.

It is important to note that the definition of "second primary neoplasm" may vary slightly depending on the specific source or context. In general medical usage, it refers to a new, separate cancer; however, in some research or clinical settings, there might be more precise criteria for defining and diagnosing second primary neoplasms.

Adenocarcinoma, mucinous is a type of cancer that begins in the glandular cells that line certain organs and produce mucin, a substance that lubricates and protects tissues. This type of cancer is characterized by the presence of abundant pools of mucin within the tumor. It typically develops in organs such as the colon, rectum, lungs, pancreas, and ovaries.

Mucinous adenocarcinomas tend to have a distinct appearance under the microscope, with large pools of mucin pushing aside the cancer cells. They may also have a different clinical behavior compared to other types of adenocarcinomas, such as being more aggressive or having a worse prognosis in some cases.

It is important to note that while a diagnosis of adenocarcinoma, mucinous can be serious, the prognosis and treatment options may vary depending on several factors, including the location of the cancer, the stage at which it was diagnosed, and the individual's overall health.

Thyroid neoplasms refer to abnormal growths or tumors in the thyroid gland, which can be benign (non-cancerous) or malignant (cancerous). These growths can vary in size and may cause a noticeable lump or nodule in the neck. Thyroid neoplasms can also affect the function of the thyroid gland, leading to hormonal imbalances and related symptoms. The exact causes of thyroid neoplasms are not fully understood, but risk factors include radiation exposure, family history, and certain genetic conditions. It is important to note that most thyroid nodules are benign, but a proper medical evaluation is necessary to determine the nature of the growth and develop an appropriate treatment plan.

Myeloproliferative disorders (MPDs) are a group of rare, chronic blood cancers that originate from the abnormal proliferation or growth of one or more types of blood-forming cells in the bone marrow. These disorders result in an overproduction of mature but dysfunctional blood cells, which can lead to serious complications such as blood clots, bleeding, and organ damage.

There are several subtypes of MPDs, including:

1. Chronic Myeloid Leukemia (CML): A disorder characterized by the overproduction of mature granulocytes (a type of white blood cell) in the bone marrow, leading to an increased number of these cells in the blood. CML is caused by a genetic mutation that results in the formation of the BCR-ABL fusion protein, which drives uncontrolled cell growth and division.
2. Polycythemia Vera (PV): A disorder characterized by the overproduction of all three types of blood cells - red blood cells, white blood cells, and platelets - in the bone marrow. This can lead to an increased risk of blood clots, bleeding, and enlargement of the spleen.
3. Essential Thrombocythemia (ET): A disorder characterized by the overproduction of platelets in the bone marrow, leading to an increased risk of blood clots and bleeding.
4. Primary Myelofibrosis (PMF): A disorder characterized by the replacement of normal bone marrow tissue with scar tissue, leading to impaired blood cell production and anemia, enlargement of the spleen, and increased risk of infections and bleeding.
5. Chronic Neutrophilic Leukemia (CNL): A rare disorder characterized by the overproduction of neutrophils (a type of white blood cell) in the bone marrow, leading to an increased number of these cells in the blood. CNL can lead to an increased risk of infections and organ damage.

MPDs are typically treated with a combination of therapies, including chemotherapy, targeted therapy, immunotherapy, and stem cell transplantation. The choice of treatment depends on several factors, including the subtype of MPD, the patient's age and overall health, and the presence of any comorbidities.

The term "DNA, neoplasm" is not a standard medical term or concept. DNA refers to deoxyribonucleic acid, which is the genetic material present in the cells of living organisms. A neoplasm, on the other hand, is a tumor or growth of abnormal tissue that can be benign (non-cancerous) or malignant (cancerous).

In some contexts, "DNA, neoplasm" may refer to genetic alterations found in cancer cells. These genetic changes can include mutations, amplifications, deletions, or rearrangements of DNA sequences that contribute to the development and progression of cancer. Identifying these genetic abnormalities can help doctors diagnose and treat certain types of cancer more effectively.

However, it's important to note that "DNA, neoplasm" is not a term that would typically be used in medical reports or research papers without further clarification. If you have any specific questions about DNA changes in cancer cells or neoplasms, I would recommend consulting with a healthcare professional or conducting further research on the topic.

Lung neoplasms refer to abnormal growths or tumors in the lung tissue. These tumors can be benign (non-cancerous) or malignant (cancerous). Malignant lung neoplasms are further classified into two main types: small cell lung carcinoma and non-small cell lung carcinoma. Lung neoplasms can cause symptoms such as cough, chest pain, shortness of breath, and weight loss. They are often caused by smoking or exposure to secondhand smoke, but can also occur due to genetic factors, radiation exposure, and other environmental carcinogens. Early detection and treatment of lung neoplasms is crucial for improving outcomes and survival rates.

Parotid neoplasms refer to abnormal growths or tumors in the parotid gland, which is the largest of the salivary glands and is located in front of the ear and extends down the neck. These neoplasms can be benign (non-cancerous) or malignant (cancerous).

Benign parotid neoplasms are typically slow-growing, painless masses that may cause facial asymmetry or difficulty in chewing or swallowing if they become large enough to compress surrounding structures. The most common type of benign parotid tumor is a pleomorphic adenoma.

Malignant parotid neoplasms, on the other hand, are more aggressive and can invade nearby tissues and spread to other parts of the body. They may present as rapidly growing masses that are firm or fixed to surrounding structures. Common types of malignant parotid tumors include mucoepidermoid carcinoma, adenoid cystic carcinoma, and squamous cell carcinoma.

The diagnosis of parotid neoplasms typically involves a thorough clinical evaluation, imaging studies such as CT or MRI scans, and fine-needle aspiration biopsy (FNAB) to determine the nature of the tumor. Treatment options depend on the type, size, and location of the neoplasm but may include surgical excision, radiation therapy, and chemotherapy.

Cystadenoma is a type of benign tumor (not cancerous), which arises from glandular epithelial cells and is covered by a thin layer of connective tissue. These tumors can develop in various locations within the body, including the ovaries, pancreas, and other organs that contain glands.

There are two main types of cystadenomas: serous and mucinous. Serous cystadenomas are filled with a clear or watery fluid, while mucinous cystadenomas contain a thick, gelatinous material. Although they are generally not harmful, these tumors can grow quite large and cause discomfort or other symptoms due to their size or location. In some cases, cystadenomas may undergo malignant transformation and develop into cancerous tumors, known as cystadenocarcinomas. Regular medical follow-up and monitoring are essential for individuals diagnosed with cystadenomas to ensure early detection and treatment of any potential complications.

Neoplasms of connective and soft tissue are abnormal growths or tumors that develop in the body's supportive tissues, such as cartilage, tendons, ligaments, fascia, and fat. These neoplasms can be benign (non-cancerous) or malignant (cancerous).

Benign connective and soft tissue neoplasms include:
- Lipomas: slow-growing, fatty tumors that develop under the skin.
- Fibromas: firm, benign tumors that develop in connective tissue such as tendons or ligaments.
- Nevi (plural of nevus): benign growths made up of cells called melanocytes, which produce pigment.

Malignant connective and soft tissue neoplasms include:
- Sarcomas: a type of cancer that develops in the body's supportive tissues such as muscle, bone, fat, cartilage, or blood vessels. There are many different types of sarcomas, including liposarcoma (fatty tissue), rhabdomyosarcoma (muscle), and osteosarcoma (bone).
- Desmoid tumors: a rare type of benign tumor that can become aggressive and invade surrounding tissues. While not considered cancerous, desmoid tumors can cause significant morbidity due to their tendency to grow and infiltrate nearby structures.

Connective and soft tissue neoplasms can present with various symptoms depending on their location and size. Treatment options include surgery, radiation therapy, chemotherapy, or a combination of these modalities. Regular follow-up care is essential to monitor for recurrence or metastasis (spread) of the tumor.

Plasma cell neoplasms are a type of cancer that originates from plasma cells, which are a type of white blood cell found in the bone marrow. These cells are responsible for producing antibodies to help fight off infections. When plasma cells become cancerous and multiply out of control, they can form a tumor called a plasmacytoma.

There are two main types of plasma cell neoplasms: solitary plasmacytoma and multiple myeloma. Solitary plasmacytoma is a localized tumor that typically forms in the bone, while multiple myeloma is a systemic disease that affects multiple bones and can cause a variety of symptoms such as bone pain, fatigue, and anemia.

Plasma cell neoplasms are diagnosed through a combination of tests, including blood tests, imaging studies, and bone marrow biopsy. Treatment options depend on the stage and extent of the disease, but may include radiation therapy, chemotherapy, and stem cell transplantation.

Appendiceal neoplasms refer to various types of tumors that can develop in the appendix, a small tube-like structure attached to the large intestine. These neoplasms can be benign or malignant and can include:

1. Adenomas: These are benign tumors that arise from the glandular cells lining the appendix. They are usually slow-growing and may not cause any symptoms.
2. Carcinoids: These are neuroendocrine tumors that arise from the hormone-producing cells in the appendix. They are typically small and slow-growing, but some can be aggressive and spread to other parts of the body.
3. Mucinous neoplasms: These are tumors that produce mucin, a slippery substance that can cause the appendix to become distended and filled with mucus. They can be low-grade (less aggressive) or high-grade (more aggressive) and may spread to other parts of the abdomen.
4. Adenocarcinomas: These are malignant tumors that arise from the glandular cells lining the appendix. They are relatively rare but can be aggressive and spread to other parts of the body.
5. Pseudomyxoma peritonei: This is a condition in which mucin produced by an appendiceal neoplasm leaks into the abdominal cavity, causing a jelly-like accumulation of fluid and tissue. It can be caused by both benign and malignant tumors.

Treatment for appendiceal neoplasms depends on the type and stage of the tumor, as well as the patient's overall health. Treatment options may include surgery, chemotherapy, or radiation therapy.

Liver neoplasms refer to abnormal growths in the liver that can be benign or malignant. Benign liver neoplasms are non-cancerous tumors that do not spread to other parts of the body, while malignant liver neoplasms are cancerous tumors that can invade and destroy surrounding tissue and spread to other organs.

Liver neoplasms can be primary, meaning they originate in the liver, or secondary, meaning they have metastasized (spread) to the liver from another part of the body. Primary liver neoplasms can be further classified into different types based on their cell of origin and behavior, including hepatocellular carcinoma, cholangiocarcinoma, and hepatic hemangioma.

The diagnosis of liver neoplasms typically involves a combination of imaging studies, such as ultrasound, CT scan, or MRI, and biopsy to confirm the type and stage of the tumor. Treatment options depend on the type and extent of the neoplasm and may include surgery, radiation therapy, chemotherapy, or liver transplantation.

Mucinous cystadenoma is a type of benign tumor that arises from the epithelial cells lining the mucous membranes of the body. It is most commonly found in the ovary, but can also occur in other locations such as the pancreas or appendix.

Mucinous cystadenomas are characterized by the production of large amounts of mucin, a slippery, gel-like substance that accumulates inside the tumor and causes it to grow into a cystic mass. These tumors can vary in size, ranging from a few centimeters to over 20 centimeters in diameter.

While mucinous cystadenomas are generally benign, they have the potential to become cancerous (mucinous cystadenocarcinoma) if left untreated. Symptoms of mucinous cystadenoma may include abdominal pain or swelling, bloating, and changes in bowel movements or urinary habits. Treatment typically involves surgical removal of the tumor.

Ovarian neoplasms refer to abnormal growths or tumors in the ovary, which can be benign (non-cancerous) or malignant (cancerous). These growths can originate from various cell types within the ovary, including epithelial cells, germ cells, and stromal cells. Ovarian neoplasms are often classified based on their cell type of origin, histological features, and potential for invasive or metastatic behavior.

Epithelial ovarian neoplasms are the most common type and can be further categorized into several subtypes, such as serous, mucinous, endometrioid, clear cell, and Brenner tumors. Some of these epithelial tumors have a higher risk of becoming malignant and spreading to other parts of the body.

Germ cell ovarian neoplasms arise from the cells that give rise to eggs (oocytes) and can include teratomas, dysgerminomas, yolk sac tumors, and embryonal carcinomas. Stromal ovarian neoplasms develop from the connective tissue cells supporting the ovary and can include granulosa cell tumors, thecomas, and fibromas.

It is essential to diagnose and treat ovarian neoplasms promptly, as some malignant forms can be aggressive and potentially life-threatening if not managed appropriately. Regular gynecological exams, imaging studies, and tumor marker tests are often used for early detection and monitoring of ovarian neoplasms. Treatment options may include surgery, chemotherapy, or radiation therapy, depending on the type, stage, and patient's overall health condition.

Endocrine gland neoplasms refer to abnormal growths (tumors) that develop in the endocrine glands. These glands are responsible for producing hormones, which are chemical messengers that regulate various functions and processes in the body. Neoplasms can be benign or malignant (cancerous). Benign neoplasms tend to grow slowly and do not spread to other parts of the body. Malignant neoplasms, on the other hand, can invade nearby tissues and organs and may also metastasize (spread) to distant sites.

Endocrine gland neoplasms can occur in any of the endocrine glands, including:

1. Pituitary gland: located at the base of the brain, it produces several hormones that regulate growth and development, as well as other bodily functions.
2. Thyroid gland: located in the neck, it produces thyroid hormones that regulate metabolism and calcium balance.
3. Parathyroid glands: located near the thyroid gland, they produce parathyroid hormone that regulates calcium levels in the blood.
4. Adrenal glands: located on top of each kidney, they produce hormones such as adrenaline, cortisol, and aldosterone that regulate stress response, metabolism, and blood pressure.
5. Pancreas: located behind the stomach, it produces insulin and glucagon, which regulate blood sugar levels, and digestive enzymes that help break down food.
6. Pineal gland: located in the brain, it produces melatonin, a hormone that regulates sleep-wake cycles.
7. Gonads (ovaries and testicles): located in the pelvis (ovaries) and scrotum (testicles), they produce sex hormones such as estrogen, progesterone, and testosterone that regulate reproductive function and secondary sexual characteristics.

Endocrine gland neoplasms can cause various symptoms depending on the type and location of the tumor. For example, a pituitary gland neoplasm may cause headaches, vision problems, or hormonal imbalances, while an adrenal gland neoplasm may cause high blood pressure, weight gain, or mood changes.

Diagnosis of endocrine gland neoplasms typically involves a combination of medical history, physical examination, imaging studies such as CT or MRI scans, and laboratory tests to measure hormone levels. Treatment options may include surgery, radiation therapy, chemotherapy, or hormonal therapy, depending on the type and stage of the tumor.

Gastrointestinal (GI) neoplasms refer to abnormal growths in the gastrointestinal tract, which can be benign or malignant. The gastrointestinal tract includes the mouth, esophagus, stomach, small intestine, large intestine, rectum, and anus.

Benign neoplasms are non-cancerous growths that do not invade nearby tissues or spread to other parts of the body. They can sometimes be removed completely and may not cause any further health problems.

Malignant neoplasms, on the other hand, are cancerous growths that can invade nearby tissues and organs and spread to other parts of the body through the bloodstream or lymphatic system. These types of neoplasms can be life-threatening if not diagnosed and treated promptly.

GI neoplasms can cause various symptoms, including abdominal pain, bloating, changes in bowel habits, nausea, vomiting, weight loss, and anemia. The specific symptoms may depend on the location and size of the neoplasm.

There are many types of GI neoplasms, including adenocarcinomas, gastrointestinal stromal tumors (GISTs), lymphomas, and neuroendocrine tumors. The diagnosis of GI neoplasms typically involves a combination of medical history, physical examination, imaging studies, and biopsy. Treatment options may include surgery, radiation therapy, chemotherapy, targeted therapy, or immunotherapy.

Pancreatic ductal carcinoma (PDC) is a specific type of cancer that forms in the ducts that carry digestive enzymes out of the pancreas. It's the most common form of exocrine pancreatic cancer, making up about 90% of all cases.

The symptoms of PDC are often vague and can include abdominal pain, jaundice (yellowing of the skin and eyes), unexplained weight loss, and changes in bowel movements. These symptoms can be similar to those caused by other less serious conditions, which can make diagnosis difficult.

Pancreatic ductal carcinoma is often aggressive and difficult to treat. The prognosis for PDC is generally poor, with a five-year survival rate of only about 9%. Treatment options may include surgery, chemotherapy, radiation therapy, or a combination of these approaches. However, because PDC is often not detected until it has advanced, treatment is frequently focused on palliative care to relieve symptoms and improve quality of life.

Experimental neoplasms refer to abnormal growths or tumors that are induced and studied in a controlled laboratory setting, typically in animals or cell cultures. These studies are conducted to understand the fundamental mechanisms of cancer development, progression, and potential treatment strategies. By manipulating various factors such as genetic mutations, environmental exposures, and pharmacological interventions, researchers can gain valuable insights into the complex processes underlying neoplasm formation and identify novel targets for cancer therapy. It is important to note that experimental neoplasms may not always accurately represent human cancers, and further research is needed to translate these findings into clinically relevant applications.

A neoplasm of vascular tissue is an abnormal growth or mass of cells in the blood vessels or lymphatic vessels. These growths can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms, such as hemangiomas and lymphangiomas, are typically not harmful and may not require treatment. However, they can cause symptoms if they grow large enough to press on nearby organs or tissues. Malignant neoplasms, such as angiosarcomas, are cancerous and can invade and destroy surrounding tissue, as well as spread (metastasize) to other parts of the body. Treatment for vascular tissue neoplasms depends on the type, size, location, and stage of the growth, and may include surgery, radiation therapy, chemotherapy, or a combination of these.

Eye neoplasms, also known as ocular tumors or eye cancer, refer to abnormal growths of tissue in the eye. These growths can be benign (non-cancerous) or malignant (cancerous). Eye neoplasms can develop in various parts of the eye, including the eyelid, conjunctiva, cornea, iris, ciliary body, choroid, retina, and optic nerve.

Benign eye neoplasms are typically slow-growing and do not spread to other parts of the body. They may cause symptoms such as vision changes, eye pain, or a noticeable mass in the eye. Treatment options for benign eye neoplasms include monitoring, surgical removal, or radiation therapy.

Malignant eye neoplasms, on the other hand, can grow and spread rapidly to other parts of the body. They may cause symptoms such as vision changes, eye pain, floaters, or flashes of light. Treatment options for malignant eye neoplasms depend on the type and stage of cancer but may include surgery, radiation therapy, chemotherapy, or a combination of these treatments.

It is important to note that early detection and treatment of eye neoplasms can improve outcomes and prevent complications. Regular eye exams with an ophthalmologist are recommended for early detection and prevention of eye diseases, including eye neoplasms.

Immunohistochemistry (IHC) is a technique used in pathology and laboratory medicine to identify specific proteins or antigens in tissue sections. It combines the principles of immunology and histology to detect the presence and location of these target molecules within cells and tissues. This technique utilizes antibodies that are specific to the protein or antigen of interest, which are then tagged with a detection system such as a chromogen or fluorophore. The stained tissue sections can be examined under a microscope, allowing for the visualization and analysis of the distribution and expression patterns of the target molecule in the context of the tissue architecture. Immunohistochemistry is widely used in diagnostic pathology to help identify various diseases, including cancer, infectious diseases, and immune-mediated disorders.

Nose neoplasms refer to abnormal growths or tumors in the nasal cavity or paranasal sinuses. These growths can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow-growing and do not spread to other parts of the body, while malignant neoplasms can invade surrounding tissues and have the potential to metastasize.

Nose neoplasms can cause various symptoms such as nasal congestion, nosebleeds, difficulty breathing through the nose, loss of smell, facial pain or numbness, and visual changes if they affect the eye. The diagnosis of nose neoplasms usually involves a combination of physical examination, imaging studies (such as CT or MRI scans), and biopsy to determine the type and extent of the growth. Treatment options depend on the type, size, location, and stage of the neoplasm and may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Salivary gland neoplasms refer to abnormal growths or tumors that develop in the salivary glands. These glands are responsible for producing saliva, which helps in digestion, lubrication of food and maintaining oral health. Salivary gland neoplasms can be benign (non-cancerous) or malignant (cancerous).

Benign neoplasms are slow-growing and typically do not spread to other parts of the body. They may cause symptoms such as swelling, painless lumps, or difficulty swallowing if they grow large enough to put pressure on surrounding tissues.

Malignant neoplasms, on the other hand, can be aggressive and have the potential to invade nearby structures and metastasize (spread) to distant organs. Symptoms of malignant salivary gland neoplasms may include rapid growth, pain, numbness, or paralysis of facial nerves.

Salivary gland neoplasms can occur in any of the major salivary glands (parotid, submandibular, and sublingual glands) or in the minor salivary glands located throughout the mouth and throat. The exact cause of these neoplasms is not fully understood, but risk factors may include exposure to radiation, certain viral infections, and genetic predisposition.

Radiation-induced neoplasms are a type of cancer or tumor that develops as a result of exposure to ionizing radiation. Ionizing radiation is radiation with enough energy to remove tightly bound electrons from atoms or molecules, leading to the formation of ions. This type of radiation can damage DNA and other cellular structures, which can lead to mutations and uncontrolled cell growth, resulting in the development of a neoplasm.

Radiation-induced neoplasms can occur after exposure to high levels of ionizing radiation, such as that received during radiation therapy for cancer treatment or from nuclear accidents. The risk of developing a radiation-induced neoplasm depends on several factors, including the dose and duration of radiation exposure, the type of radiation, and the individual's genetic susceptibility to radiation-induced damage.

Radiation-induced neoplasms can take many years to develop after initial exposure to ionizing radiation, and they often occur at the site of previous radiation therapy. Common types of radiation-induced neoplasms include sarcomas, carcinomas, and thyroid cancer. It is important to note that while ionizing radiation can increase the risk of developing cancer, the overall risk is still relatively low, especially when compared to other well-established cancer risk factors such as smoking and exposure to certain chemicals.

Adenocarcinoma, papillary is a type of cancer that begins in the glandular cells and grows in a finger-like projection (called a papilla). This type of cancer can occur in various organs, including the lungs, pancreas, thyroid, and female reproductive system. The prognosis and treatment options for papillary adenocarcinoma depend on several factors, such as the location and stage of the tumor, as well as the patient's overall health. It is important to consult with a healthcare professional for an accurate diagnosis and personalized treatment plan.

Carcinoma, papillary is a type of cancer that begins in the cells that line the glandular structures or the lining of organs. In a papillary carcinoma, the cancerous cells grow and form small finger-like projections, called papillae, within the tumor. This type of cancer most commonly occurs in the thyroid gland, but can also be found in other organs such as the lung, breast, and kidney. Papillary carcinoma of the thyroid gland is usually slow-growing and has a good prognosis, especially when it is diagnosed at an early stage.

Testicular neoplasms are abnormal growths or tumors in the testicle that can be benign (non-cancerous) or malignant (cancerous). They are a type of genitourinary cancer, which affects the reproductive and urinary systems. Testicular neoplasms can occur in men of any age but are most commonly found in young adults between the ages of 15 and 40.

Testicular neoplasms can be classified into two main categories: germ cell tumors and non-germ cell tumors. Germ cell tumors, which arise from the cells that give rise to sperm, are further divided into seminomas and non-seminomas. Seminomas are typically slow-growing and have a good prognosis, while non-seminomas tend to grow more quickly and can spread to other parts of the body.

Non-germ cell tumors are less common than germ cell tumors and include Leydig cell tumors, Sertoli cell tumors, and lymphomas. These tumors can have a variety of clinical behaviors, ranging from benign to malignant.

Testicular neoplasms often present as a painless mass or swelling in the testicle. Other symptoms may include a feeling of heaviness or discomfort in the scrotum, a dull ache in the lower abdomen or groin, and breast enlargement (gynecomastia).

Diagnosis typically involves a physical examination, imaging studies such as ultrasound or CT scan, and blood tests to detect tumor markers. Treatment options depend on the type and stage of the neoplasm but may include surgery, radiation therapy, chemotherapy, or a combination of these modalities. Regular self-examinations of the testicles are recommended for early detection and improved outcomes.

Neoplasms in muscle tissue refer to abnormal and excessive growths of muscle cells that can be benign or malignant. These growths can arise from any of the three types of muscle tissue: skeletal, cardiac, or smooth muscle. Neoplasms in muscle tissue are classified based on their origin, behavior, and histological features.

Benign neoplasms in muscle tissue include leiomyomas (smooth muscle), rhabdomyomas (skeletal muscle), and myxomas (cardiac muscle). These tumors are usually slow-growing and do not invade surrounding tissues or spread to other parts of the body.

Malignant neoplasms in muscle tissue, also known as sarcomas, include leiomyosarcoma (smooth muscle), rhabdomyosarcoma (skeletal muscle), and angiosarcoma (cardiac muscle). These tumors are aggressive, invasive, and have the potential to metastasize to other parts of the body.

Symptoms of neoplasms in muscle tissue depend on their location, size, and type. They may include a painless or painful mass, weakness, fatigue, weight loss, and difficulty swallowing or breathing. Treatment options for neoplasms in muscle tissue include surgery, radiation therapy, chemotherapy, and targeted therapy. The choice of treatment depends on the type, stage, location, and patient's overall health condition.

Neoplasms are abnormal growths of cells or tissues that serve no purpose and can be benign (non-cancerous) or malignant (cancerous). Glandular and epithelial neoplasms refer to specific types of tumors that originate from the glandular and epithelial tissues, respectively.

Glandular neoplasms arise from the glandular tissue, which is responsible for producing and secreting substances such as hormones, enzymes, or other fluids. These neoplasms can be further classified into adenomas (benign) and adenocarcinomas (malignant).

Epithelial neoplasms, on the other hand, develop from the epithelial tissue that lines the outer surfaces of organs and the inner surfaces of cavities. These neoplasms can also be benign or malignant and are classified as papillomas (benign) and carcinomas (malignant).

It is important to note that while both glandular and epithelial neoplasms can become cancerous, not all of them do. However, if they do, the malignant versions can invade surrounding tissues and spread to other parts of the body, making them potentially life-threatening.

Mucinous cystadenocarcinoma is a type of cancer that arises from the mucin-producing cells in the lining of a cyst. It is a subtype of cystadenocarcinoma, which is a malignant tumor that develops within a cyst. Mucinous cystadenocarcinomas are typically found in the ovary or pancreas but can also occur in other organs such as the appendix and the respiratory tract.

These tumors are characterized by the production of large amounts of mucin, a gel-like substance that can accumulate within the cyst and cause it to grow. Mucinous cystadenocarcinomas tend to grow slowly but can become quite large and may eventually spread (metastasize) to other parts of the body if left untreated.

Symptoms of mucinous cystadenocarcinoma depend on the location and size of the tumor, but they may include abdominal pain or discomfort, bloating, changes in bowel movements, or vaginal bleeding. Treatment typically involves surgical removal of the tumor, followed by chemotherapy or radiation therapy to kill any remaining cancer cells. The prognosis for mucinous cystadenocarcinoma depends on several factors, including the stage of the disease at diagnosis and the patient's overall health.

An adenoma is a benign (noncancerous) tumor that develops from glandular epithelial cells. These types of cells are responsible for producing and releasing fluids, such as hormones or digestive enzymes, into the surrounding tissues. Adenomas can occur in various organs and glands throughout the body, including the thyroid, pituitary, adrenal, and digestive systems.

Depending on their location, adenomas may cause different symptoms or remain asymptomatic. Some common examples of adenomas include:

1. Colorectal adenoma (also known as a polyp): These growths occur in the lining of the colon or rectum and can develop into colorectal cancer if left untreated. Regular screenings, such as colonoscopies, are essential for early detection and removal of these polyps.
2. Thyroid adenoma: This type of adenoma affects the thyroid gland and may result in an overproduction or underproduction of hormones, leading to conditions like hyperthyroidism (overactive thyroid) or hypothyroidism (underactive thyroid).
3. Pituitary adenoma: These growths occur in the pituitary gland, which is located at the base of the brain and controls various hormonal functions. Depending on their size and location, pituitary adenomas can cause vision problems, headaches, or hormonal imbalances that affect growth, reproduction, and metabolism.
4. Liver adenoma: These rare benign tumors develop in the liver and may not cause any symptoms unless they become large enough to press on surrounding organs or structures. In some cases, liver adenomas can rupture and cause internal bleeding.
5. Adrenal adenoma: These growths occur in the adrenal glands, which are located above the kidneys and produce hormones that regulate stress responses, metabolism, and blood pressure. Most adrenal adenomas are nonfunctioning, meaning they do not secrete excess hormones. However, functioning adrenal adenomas can lead to conditions like Cushing's syndrome or Conn's syndrome, depending on the type of hormone being overproduced.

It is essential to monitor and manage benign tumors like adenomas to prevent potential complications, such as rupture, bleeding, or hormonal imbalances. Treatment options may include surveillance with imaging studies, medication to manage hormonal issues, or surgical removal of the tumor in certain cases.

Soft tissue neoplasms refer to abnormal growths or tumors that develop in the soft tissues of the body. Soft tissues include muscles, tendons, ligaments, fascia, nerves, blood vessels, fat, and synovial membranes (the thin layer of cells that line joints and tendons). Neoplasms can be benign (non-cancerous) or malignant (cancerous), and their behavior and potential for spread depend on the specific type of neoplasm.

Benign soft tissue neoplasms are typically slow-growing, well-circumscribed, and rarely spread to other parts of the body. They can often be removed surgically with a low risk of recurrence. Examples of benign soft tissue neoplasms include lipomas (fat tumors), schwannomas (nerve sheath tumors), and hemangiomas (blood vessel tumors).

Malignant soft tissue neoplasms, on the other hand, can grow rapidly, invade surrounding tissues, and may metastasize (spread) to distant parts of the body. They are often more difficult to treat than benign neoplasms and require a multidisciplinary approach, including surgery, radiation therapy, and chemotherapy. Examples of malignant soft tissue neoplasms include sarcomas, such as rhabdomyosarcoma (arising from skeletal muscle), leiomyosarcoma (arising from smooth muscle), and angiosarcoma (arising from blood vessels).

It is important to note that soft tissue neoplasms can occur in any part of the body, and their diagnosis and treatment require a thorough evaluation by a healthcare professional with expertise in this area.

Hematologic neoplasms, also known as hematological malignancies, are a group of diseases characterized by the uncontrolled growth and accumulation of abnormal blood cells or bone marrow cells. These disorders can originate from the myeloid or lymphoid cell lines, which give rise to various types of blood cells, including red blood cells, white blood cells, and platelets.

Hematologic neoplasms can be broadly classified into three categories:

1. Leukemias: These are cancers that primarily affect the bone marrow and blood-forming tissues. They result in an overproduction of abnormal white blood cells, which interfere with the normal functioning of the blood and immune system. There are several types of leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML).
2. Lymphomas: These are cancers that develop from the lymphatic system, which is a part of the immune system responsible for fighting infections. Lymphomas can affect lymph nodes, spleen, bone marrow, and other organs. The two main types of lymphoma are Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).
3. Myelomas: These are cancers that arise from the plasma cells, a type of white blood cell responsible for producing antibodies. Multiple myeloma is the most common type of myeloma, characterized by an excessive proliferation of malignant plasma cells in the bone marrow, leading to the production of abnormal amounts of monoclonal immunoglobulins (M proteins) and bone destruction.

Hematologic neoplasms can have various symptoms, such as fatigue, weakness, frequent infections, easy bruising or bleeding, weight loss, swollen lymph nodes, and bone pain. The diagnosis typically involves a combination of medical history, physical examination, laboratory tests, imaging studies, and sometimes bone marrow biopsy. Treatment options depend on the type and stage of the disease and may include chemotherapy, radiation therapy, targeted therapy, immunotherapy, stem cell transplantation, or a combination of these approaches.

A neoplasm is a tumor or growth that is formed by an abnormal and excessive proliferation of cells, which can be benign or malignant. Neoplasm proteins are therefore any proteins that are expressed or produced in these neoplastic cells. These proteins can play various roles in the development, progression, and maintenance of neoplasms.

Some neoplasm proteins may contribute to the uncontrolled cell growth and division seen in cancer, such as oncogenic proteins that promote cell cycle progression or inhibit apoptosis (programmed cell death). Others may help the neoplastic cells evade the immune system, allowing them to proliferate undetected. Still others may be involved in angiogenesis, the formation of new blood vessels that supply the tumor with nutrients and oxygen.

Neoplasm proteins can also serve as biomarkers for cancer diagnosis, prognosis, or treatment response. For example, the presence or level of certain neoplasm proteins in biological samples such as blood or tissue may indicate the presence of a specific type of cancer, help predict the likelihood of cancer recurrence, or suggest whether a particular therapy will be effective.

Overall, understanding the roles and behaviors of neoplasm proteins can provide valuable insights into the biology of cancer and inform the development of new diagnostic and therapeutic strategies.

Uterine neoplasms refer to abnormal growths in the uterus, which can be benign (non-cancerous) or malignant (cancerous). These growths can originate from different types of cells within the uterus, leading to various types of uterine neoplasms. The two main categories of uterine neoplasms are endometrial neoplasms and uterine sarcomas.

Endometrial neoplasms develop from the endometrium, which is the inner lining of the uterus. Most endometrial neoplasms are classified as endometrioid adenocarcinomas, arising from glandular cells in the endometrium. Other types include serous carcinoma, clear cell carcinoma, and mucinous carcinoma.

Uterine sarcomas, on the other hand, are less common and originate from the connective tissue (stroma) or muscle (myometrium) of the uterus. Uterine sarcomas can be further divided into several subtypes, such as leiomyosarcoma, endometrial stromal sarcoma, and undifferentiated uterine sarcoma.

Uterine neoplasms can cause various symptoms, including abnormal vaginal bleeding or discharge, pelvic pain, and difficulty urinating or having bowel movements. The diagnosis typically involves a combination of imaging tests (such as ultrasound, CT, or MRI scans) and tissue biopsies to determine the type and extent of the neoplasm. Treatment options depend on the type, stage, and patient's overall health but may include surgery, radiation therapy, chemotherapy, or hormone therapy.

Intestinal neoplasms refer to abnormal growths in the tissues of the intestines, which can be benign or malignant. These growths are called neoplasms and they result from uncontrolled cell division. In the case of intestinal neoplasms, these growths occur in the small intestine, large intestine (colon), rectum, or appendix.

Benign intestinal neoplasms are not cancerous and often do not invade surrounding tissues or spread to other parts of the body. However, they can still cause problems if they grow large enough to obstruct the intestines or cause bleeding. Common types of benign intestinal neoplasms include polyps, leiomyomas, and lipomas.

Malignant intestinal neoplasms, on the other hand, are cancerous and can invade surrounding tissues and spread to other parts of the body. The most common type of malignant intestinal neoplasm is adenocarcinoma, which arises from the glandular cells lining the inside of the intestines. Other types of malignant intestinal neoplasms include lymphomas, sarcomas, and carcinoid tumors.

Symptoms of intestinal neoplasms can vary depending on their size, location, and type. Common symptoms include abdominal pain, bloating, changes in bowel habits, rectal bleeding, weight loss, and fatigue. If you experience any of these symptoms, it is important to seek medical attention promptly.

Neoplasms, adnexal and skin appendage refer to abnormal growths or tumors that develop in the sweat glands, hair follicles, or other structures associated with the skin. These growths can be benign (non-cancerous) or malignant (cancerous), and they can occur anywhere on the body.

Adnexal neoplasms are tumors that arise from the sweat glands or hair follicles, including the sebaceous glands, eccrine glands, and apocrine glands. These tumors can range in size and severity, and they may cause symptoms such as pain, itching, or changes in the appearance of the skin.

Skin appendage neoplasms are similar to adnexal neoplasms, but they specifically refer to tumors that arise from structures such as hair follicles, nails, and sweat glands. Examples of skin appendage neoplasms include pilomatricomas (tumors of the hair follicle), trichilemmomas (tumors of the outer root sheath of the hair follicle), and sebaceous adenomas (tumors of the sebaceous glands).

It is important to note that while many adnexal and skin appendage neoplasms are benign, some can be malignant and may require aggressive treatment. If you notice any unusual growths or changes in your skin, it is important to consult with a healthcare professional for further evaluation and care.

Neoplasm staging is a systematic process used in medicine to describe the extent of spread of a cancer, including the size and location of the original (primary) tumor and whether it has metastasized (spread) to other parts of the body. The most widely accepted system for this purpose is the TNM classification system developed by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC).

In this system, T stands for tumor, and it describes the size and extent of the primary tumor. N stands for nodes, and it indicates whether the cancer has spread to nearby lymph nodes. M stands for metastasis, and it shows whether the cancer has spread to distant parts of the body.

Each letter is followed by a number that provides more details about the extent of the disease. For example, a T1N0M0 cancer means that the primary tumor is small and has not spread to nearby lymph nodes or distant sites. The higher the numbers, the more advanced the cancer.

Staging helps doctors determine the most appropriate treatment for each patient and estimate the patient's prognosis. It is an essential tool for communication among members of the healthcare team and for comparing outcomes of treatments in clinical trials.

Vascular neoplasms are a type of tumor that develops from cells that line the blood vessels or lymphatic vessels. These tumors can be benign (non-cancerous) or malignant (cancerous). Benign vascular neoplasms, such as hemangiomas and lymphangiomas, are usually harmless and may not require treatment unless they cause symptoms or complications. Malignant vascular neoplasms, on the other hand, are known as angiosarcomas and can be aggressive, spreading to other parts of the body and potentially causing serious health problems.

Angiosarcomas can develop in any part of the body but are most commonly found in the skin, particularly in areas exposed to radiation or chronic lymph edema. They can also occur in the breast, liver, spleen, and heart. Treatment for vascular neoplasms depends on the type, location, size, and stage of the tumor, as well as the patient's overall health. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Sweat gland neoplasms are abnormal growths that develop in the sweat glands. These growths can be benign (noncancerous) or malignant (cancerous). Benign sweat gland neoplasms include hidradenomas and syringomas, which are usually slow-growing and cause little to no symptoms. Malignant sweat gland neoplasms, also known as sweat gland carcinomas, are rare but aggressive cancers that can spread to other parts of the body. They may cause symptoms such as a lump or mass under the skin, pain, swelling, and redness. Treatment typically involves surgical removal of the growth.

Lymphoma is a type of cancer that originates from the white blood cells called lymphocytes, which are part of the immune system. These cells are found in various parts of the body such as the lymph nodes, spleen, bone marrow, and other organs. Lymphoma can be classified into two main types: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

HL is characterized by the presence of a specific type of abnormal lymphocyte called Reed-Sternberg cells, while NHL includes a diverse group of lymphomas that lack these cells. The symptoms of lymphoma may include swollen lymph nodes, fever, night sweats, weight loss, and fatigue.

The exact cause of lymphoma is not known, but it is believed to result from genetic mutations in the lymphocytes that lead to uncontrolled cell growth and division. Exposure to certain viruses, chemicals, and radiation may increase the risk of developing lymphoma. Treatment options for lymphoma depend on various factors such as the type and stage of the disease, age, and overall health of the patient. Common treatments include chemotherapy, radiation therapy, immunotherapy, and stem cell transplantation.

Bone neoplasms are abnormal growths or tumors that develop in the bone. They can be benign (non-cancerous) or malignant (cancerous). Benign bone neoplasms do not spread to other parts of the body and are rarely a threat to life, although they may cause problems if they grow large enough to press on surrounding tissues or cause fractures. Malignant bone neoplasms, on the other hand, can invade and destroy nearby tissue and may spread (metastasize) to other parts of the body.

There are many different types of bone neoplasms, including:

1. Osteochondroma - a benign tumor that develops from cartilage and bone
2. Enchondroma - a benign tumor that forms in the cartilage that lines the inside of the bones
3. Chondrosarcoma - a malignant tumor that develops from cartilage
4. Osteosarcoma - a malignant tumor that develops from bone cells
5. Ewing sarcoma - a malignant tumor that develops in the bones or soft tissues around the bones
6. Giant cell tumor of bone - a benign or occasionally malignant tumor that develops from bone tissue
7. Fibrosarcoma - a malignant tumor that develops from fibrous tissue in the bone

The symptoms of bone neoplasms vary depending on the type, size, and location of the tumor. They may include pain, swelling, stiffness, fractures, or limited mobility. Treatment options depend on the type and stage of the tumor but may include surgery, radiation therapy, chemotherapy, or a combination of these treatments.

Palatal neoplasms refer to abnormal growths or tumors that occur on the palate, which is the roof of the mouth. These growths can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slower growing and less likely to spread, while malignant neoplasms are more aggressive and can invade nearby tissues and organs.

Palatal neoplasms can have various causes, including genetic factors, environmental exposures, and viral infections. They may present with symptoms such as mouth pain, difficulty swallowing, swelling or lumps in the mouth, bleeding, or numbness in the mouth or face.

The diagnosis of palatal neoplasms typically involves a thorough clinical examination, imaging studies, and sometimes biopsy to determine the type and extent of the growth. Treatment options depend on the type, size, location, and stage of the neoplasm but may include surgery, radiation therapy, chemotherapy, or a combination of these approaches. Regular follow-up care is essential to monitor for recurrence or spread of the neoplasm.

Neoplasms are abnormal growths of cells or tissues in the body that can be benign (non-cancerous) or malignant (cancerous). When referring to "Complex and Mixed Neoplasms," it is typically used in the context of histopathology, where it describes tumors with a mixture of different types of cells or growth patterns.

A complex neoplasm usually contains areas with various architectural patterns, cell types, or both, making its classification challenging. It may require extensive sampling and careful examination to determine its nature and behavior. These neoplasms can be either benign or malignant, depending on the specific characteristics of the tumor cells and their growth pattern.

A mixed neoplasm, on the other hand, is a tumor that contains more than one type of cell or tissue component, often arising from different germ layers (the three primary layers of embryonic development: ectoderm, mesoderm, and endoderm). A common example of a mixed neoplasm is a teratoma, which can contain tissues derived from all three germ layers, such as skin, hair, teeth, bone, and muscle. Mixed neoplasms can also be benign or malignant, depending on the specific components of the tumor.

It's important to note that the classification and behavior of complex and mixed neoplasms can vary significantly based on their location in the body, cellular composition, and other factors. Accurate diagnosis typically requires a thorough examination by an experienced pathologist and may involve additional tests, such as immunohistochemistry or molecular analysis, to determine the appropriate treatment and management strategies.

Neoplasm antigens, also known as tumor antigens, are substances that are produced by cancer cells (neoplasms) and can stimulate an immune response. These antigens can be proteins, carbohydrates, or other molecules that are either unique to the cancer cells or are overexpressed or mutated versions of normal cellular proteins.

Neoplasm antigens can be classified into two main categories: tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs). TSAs are unique to cancer cells and are not expressed by normal cells, while TAAs are present at low levels in normal cells but are overexpressed or altered in cancer cells.

TSAs can be further divided into viral antigens and mutated antigens. Viral antigens are produced when cancer is caused by a virus, such as human papillomavirus (HPV) in cervical cancer. Mutated antigens are the result of genetic mutations that occur during cancer development and are unique to each patient's tumor.

Neoplasm antigens play an important role in the immune response against cancer. They can be recognized by the immune system, leading to the activation of immune cells such as T cells and natural killer (NK) cells, which can then attack and destroy cancer cells. However, cancer cells often develop mechanisms to evade the immune response, allowing them to continue growing and spreading.

Understanding neoplasm antigens is important for the development of cancer immunotherapies, which aim to enhance the body's natural immune response against cancer. These therapies include checkpoint inhibitors, which block proteins that inhibit T cell activation, and therapeutic vaccines, which stimulate an immune response against specific tumor antigens.

Mandibular neoplasms refer to abnormal growths or tumors that develop in the mandible, which is the lower jawbone. These growths can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow-growing and rarely spread to other parts of the body, while malignant neoplasms can invade surrounding tissues and may metastasize (spread) to distant sites.

Mandibular neoplasms can have various causes, including genetic mutations, exposure to certain chemicals or radiation, and infection with certain viruses. The symptoms of mandibular neoplasms may include swelling or pain in the jaw, difficulty chewing or speaking, numbness in the lower lip or chin, loose teeth, and/or a lump or mass in the mouth or neck.

The diagnosis of mandibular neoplasms typically involves a thorough clinical examination, imaging studies such as X-rays, CT scans, or MRI scans, and sometimes a biopsy to confirm the type and extent of the tumor. Treatment options depend on the type, stage, and location of the neoplasm, and may include surgery, radiation therapy, chemotherapy, or a combination of these approaches. Regular follow-up care is essential to monitor for recurrence or metastasis.

Cystadenocarcinoma is a type of tumor that arises from the epithelial lining of a cyst, and it has the potential to invade surrounding tissues and spread (metastasize) to other parts of the body. It typically affects glandular organs such as the ovaries, pancreas, and salivary glands.

Cystadenocarcinomas can be classified into two types: serous and mucinous. Serous cystadenocarcinomas produce a watery fluid, while mucinous cystadenocarcinomas produce a thick, mucus-like fluid. Both types of tumors can be benign or malignant, but malignant cystadenocarcinomas are more aggressive and have a higher risk of metastasis.

Symptoms of cystadenocarcinoma depend on the location and size of the tumor. In some cases, there may be no symptoms until the tumor has grown large enough to cause pain or other problems. Treatment typically involves surgical removal of the tumor, along with any affected surrounding tissue. Chemotherapy and radiation therapy may also be used in some cases to help prevent recurrence or spread of the cancer.

Bile duct neoplasms, also known as cholangiocarcinomas, refer to a group of malignancies that arise from the bile ducts. These are the tubes that carry bile from the liver to the gallbladder and small intestine. Bile duct neoplasms can be further classified based on their location as intrahepatic (within the liver), perihilar (at the junction of the left and right hepatic ducts), or distal (in the common bile duct).

These tumors are relatively rare, but their incidence has been increasing in recent years. They can cause a variety of symptoms, including jaundice, abdominal pain, weight loss, and fever. The diagnosis of bile duct neoplasms typically involves imaging studies such as CT or MRI scans, as well as blood tests to assess liver function. In some cases, a biopsy may be necessary to confirm the diagnosis.

Treatment options for bile duct neoplasms depend on several factors, including the location and stage of the tumor, as well as the patient's overall health. Surgical resection is the preferred treatment for early-stage tumors, while chemotherapy and radiation therapy may be used in more advanced cases. For patients who are not candidates for surgery, palliative treatments such as stenting or bypass procedures may be recommended to relieve symptoms and improve quality of life.

Neoplasm invasiveness is a term used in pathology and oncology to describe the aggressive behavior of cancer cells as they invade surrounding tissues and organs. This process involves the loss of cell-to-cell adhesion, increased motility and migration, and the ability of cancer cells to degrade the extracellular matrix (ECM) through the production of enzymes such as matrix metalloproteinases (MMPs).

Invasive neoplasms are cancers that have spread beyond the original site where they first developed and have infiltrated adjacent tissues or structures. This is in contrast to non-invasive or in situ neoplasms, which are confined to the epithelial layer where they originated and have not yet invaded the underlying basement membrane.

The invasiveness of a neoplasm is an important prognostic factor in cancer diagnosis and treatment, as it can indicate the likelihood of metastasis and the potential effectiveness of various therapies. In general, more invasive cancers are associated with worse outcomes and require more aggressive treatment approaches.

Thymus neoplasms are abnormal growths in the thymus gland that result from uncontrolled cell division. The term "neoplasm" refers to any new and abnormal growth of tissue, also known as a tumor. Thymus neoplasms can be benign or malignant (cancerous).

Malignant thymus neoplasms are called thymomas or thymic carcinomas. Thymomas are the most common type and tend to grow slowly, invading nearby tissues and organs. They can also spread (metastasize) to other parts of the body. Thymic carcinomas are rarer and more aggressive, growing and spreading more quickly than thymomas.

Symptoms of thymus neoplasms may include coughing, chest pain, difficulty breathing, or swelling in the neck or upper chest. Treatment options for thymus neoplasms depend on the type, size, location, and stage of the tumor, as well as the patient's overall health. Treatment may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Splenic neoplasms refer to abnormal growths or tumors in the spleen, which can be benign (non-cancerous) or malignant (cancerous). These growths can arise from various cell types present within the spleen, including hematopoietic cells (red and white blood cells, platelets), stromal cells (supporting tissue), or lymphoid cells (part of the immune system).

There are several types of splenic neoplasms:

1. Hematologic malignancies: These are cancers that affect the blood and bone marrow, such as leukemias, lymphomas, and multiple myeloma. They often involve the spleen, causing enlargement (splenomegaly) and neoplastic infiltration of splenic tissue.
2. Primary splenic tumors: These are rare and include benign lesions like hemangiomas, lymphangiomas, and hamartomas, as well as malignant tumors such as angiosarcoma, littoral cell angiosarcoma, and primary splenic lymphoma.
3. Metastatic splenic tumors: These occur when cancer cells from other primary sites spread (metastasize) to the spleen. Common sources of metastasis include lung, breast, colon, and ovarian cancers, as well as melanomas and sarcomas.

Symptoms of splenic neoplasms may vary depending on the type and extent of the disease but often include abdominal pain or discomfort, fatigue, weight loss, and anemia. Diagnosis typically involves imaging studies (such as ultrasound, CT, or MRI scans) and sometimes requires a biopsy for confirmation. Treatment options depend on the type of neoplasm and may include surgery, chemotherapy, radiation therapy, targeted therapy, or immunotherapy.

Heart neoplasms are abnormal growths or tumors that develop within the heart tissue. They can be benign (noncancerous) or malignant (cancerous). Benign tumors, such as myxomas and rhabdomyomas, are typically slower growing and less likely to spread, but they can still cause serious complications if they obstruct blood flow or damage heart valves. Malignant tumors, such as angiosarcomas and rhabdomyosarcomas, are fast-growing and have a higher risk of spreading to other parts of the body. Symptoms of heart neoplasms can include shortness of breath, chest pain, fatigue, and irregular heart rhythms. Treatment options depend on the type, size, and location of the tumor, and may include surgery, radiation therapy, or chemotherapy.

A serous cystadenoma is a type of benign tumor that arises from the epithelial cells lining the serous glands, which are glands that produce a watery, lubricating fluid. This type of tumor typically develops in the ovary or the pancreas.

Serous cystadenomas of the ovary are usually filled with a clear, watery fluid and have multiple loculations (compartments). They can vary in size from a few millimeters to several centimeters in diameter. Although these tumors are benign, they can cause symptoms if they become large enough to press on surrounding organs or if they rupture and release their contents into the abdominal cavity.

Serous cystadenomas of the pancreas are less common than ovarian serous cystadenomas. They typically occur in the tail of the pancreas and can range in size from a few millimeters to several centimeters in diameter. These tumors are usually asymptomatic, but they can cause symptoms such as abdominal pain or discomfort if they become large enough to press on surrounding organs.

It is important to note that while serous cystadenomas are generally benign, there is a small risk that they may undergo malignant transformation and develop into a type of cancer known as a serous cystadenocarcinoma. For this reason, it is important for patients with these tumors to be followed closely by a healthcare provider and to have regular imaging studies and/or surgical excision to monitor for any changes in the tumor.

Colonic neoplasms refer to abnormal growths in the large intestine, also known as the colon. These growths can be benign (non-cancerous) or malignant (cancerous). The two most common types of colonic neoplasms are adenomas and carcinomas.

Adenomas are benign tumors that can develop into cancer over time if left untreated. They are often found during routine colonoscopies and can be removed during the procedure.

Carcinomas, on the other hand, are malignant tumors that invade surrounding tissues and can spread to other parts of the body. Colorectal cancer is the third leading cause of cancer-related deaths in the United States, and colonic neoplasms are a significant risk factor for developing this type of cancer.

Regular screenings for colonic neoplasms are recommended for individuals over the age of 50 or those with a family history of colorectal cancer or other risk factors. Early detection and removal of colonic neoplasms can significantly reduce the risk of developing colorectal cancer.

Maxillary neoplasms refer to abnormal growths or tumors in the maxilla, which is the upper jaw bone. These growths can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are slow-growing and do not spread to other parts of the body, while malignant neoplasms can invade surrounding tissues and spread to distant sites.

Maxillary neoplasms can cause various symptoms such as swelling, pain, numbness, loose teeth, or difficulty in chewing or swallowing. They may also cause nasal congestion, nosebleeds, or visual changes if they affect the eye or orbit. The diagnosis of maxillary neoplasms usually involves a combination of clinical examination, imaging studies such as CT or MRI scans, and biopsy to determine the type and extent of the tumor.

Treatment options for maxillary neoplasms depend on several factors, including the type, size, location, and stage of the tumor, as well as the patient's overall health and preferences. Treatment may include surgery, radiation therapy, chemotherapy, or a combination of these modalities. Regular follow-up care is essential to monitor for recurrence or metastasis and ensure optimal outcomes.

Tumor markers are substances that can be found in the body and their presence can indicate the presence of certain types of cancer or other conditions. Biological tumor markers refer to those substances that are produced by cancer cells or by other cells in response to cancer or certain benign (non-cancerous) conditions. These markers can be found in various bodily fluids such as blood, urine, or tissue samples.

Examples of biological tumor markers include:

1. Proteins: Some tumor markers are proteins that are produced by cancer cells or by other cells in response to the presence of cancer. For example, prostate-specific antigen (PSA) is a protein produced by normal prostate cells and in higher amounts by prostate cancer cells.
2. Genetic material: Tumor markers can also include genetic material such as DNA, RNA, or microRNA that are shed by cancer cells into bodily fluids. For example, circulating tumor DNA (ctDNA) is genetic material from cancer cells that can be found in the bloodstream.
3. Metabolites: Tumor markers can also include metabolic products produced by cancer cells or by other cells in response to cancer. For example, lactate dehydrogenase (LDH) is an enzyme that is released into the bloodstream when cancer cells break down glucose for energy.

It's important to note that tumor markers are not specific to cancer and can be elevated in non-cancerous conditions as well. Therefore, they should not be used alone to diagnose cancer but rather as a tool in conjunction with other diagnostic tests and clinical evaluations.

There is no medical definition for "dog diseases" as it is too broad a term. However, dogs can suffer from various health conditions and illnesses that are specific to their species or similar to those found in humans. Some common categories of dog diseases include:

1. Infectious Diseases: These are caused by viruses, bacteria, fungi, or parasites. Examples include distemper, parvovirus, kennel cough, Lyme disease, and heartworms.
2. Hereditary/Genetic Disorders: Some dogs may inherit certain genetic disorders from their parents. Examples include hip dysplasia, elbow dysplasia, progressive retinal atrophy (PRA), and degenerative myelopathy.
3. Age-Related Diseases: As dogs age, they become more susceptible to various health issues. Common age-related diseases in dogs include arthritis, dental disease, cancer, and cognitive dysfunction syndrome (CDS).
4. Nutritional Disorders: Malnutrition or improper feeding can lead to various health problems in dogs. Examples include obesity, malnutrition, and vitamin deficiencies.
5. Environmental Diseases: These are caused by exposure to environmental factors such as toxins, allergens, or extreme temperatures. Examples include heatstroke, frostbite, and toxicities from ingesting harmful substances.
6. Neurological Disorders: Dogs can suffer from various neurological conditions that affect their nervous system. Examples include epilepsy, intervertebral disc disease (IVDD), and vestibular disease.
7. Behavioral Disorders: Some dogs may develop behavioral issues due to various factors such as anxiety, fear, or aggression. Examples include separation anxiety, noise phobias, and resource guarding.

It's important to note that regular veterinary care, proper nutrition, exercise, and preventative measures can help reduce the risk of many dog diseases.

Anal gland neoplasms, also known as anal sac tumors, are abnormal growths that develop from the cells lining the anal glands. These glands are located on either side of the anus in dogs and some other animals, and they produce a scent used for marking territory.

Anal gland neoplasms can be benign or malignant (cancerous). Malignant tumors are more common and tend to grow quickly, invading surrounding tissues and spreading to other parts of the body (metastasis). Common symptoms of anal gland neoplasms include straining to defecate, bleeding from the rectum, and a firm mass that can be felt near the anus.

Treatment for anal gland neoplasms typically involves surgical removal of the tumor. In some cases, radiation therapy or chemotherapy may also be recommended. The prognosis for animals with anal gland neoplasms depends on several factors, including the size and location of the tumor, whether it has spread to other parts of the body, and the overall health of the animal.

Neoplasms, germ cell and embryonal are types of tumors that originate from the abnormal growth of cells. Here's a brief medical definition for each:

1. Neoplasms: Neoplasms refer to abnormal tissue growths or masses, which can be benign (non-cancerous) or malignant (cancerous). They result from uncontrolled cell division and may invade surrounding tissues or spread to other parts of the body through a process called metastasis.
2. Germ Cell Tumors: These are rare tumors that develop from the germ cells, which give rise to sperm and eggs in the reproductive organs (ovaries and testes). They can be benign or malignant and may occur in both children and adults. Germ cell tumors can also arise outside of the reproductive organs, a condition known as extragonadal germ cell tumors.
3. Embryonal Tumors: These are a type of malignant neoplasm that primarily affects infants and young children. They develop from embryonic cells, which are immature cells present during fetal development. Embryonal tumors can occur in various organs, including the brain (medulloblastomas), nervous system (primitive neuroectodermal tumors or PNETs), and other areas like the kidneys and liver.

It is essential to note that these conditions require professional medical evaluation and treatment by healthcare professionals with expertise in oncology and related fields.

Bone marrow neoplasms are a type of cancer that originates in the bone marrow, which is the spongy tissue inside bones where blood cells are produced. These neoplasms can be divided into two main categories: hematologic (or liquid) malignancies and solid tumors.

Hematologic malignancies include leukemias, lymphomas, and multiple myeloma. Leukemias are cancers of the white blood cells, which normally fight infections. In leukemia, the bone marrow produces abnormal white blood cells that do not function properly, leading to an increased risk of infection, anemia, and bleeding.

Lymphomas are cancers of the lymphatic system, which helps to fight infections and remove waste from the body. Lymphoma can affect the lymph nodes, spleen, thymus gland, and bone marrow. There are two main types of lymphoma: Hodgkin's lymphoma and non-Hodgkin's lymphoma.

Multiple myeloma is a cancer of the plasma cells, which are a type of white blood cell that produces antibodies to help fight infections. In multiple myeloma, abnormal plasma cells accumulate in the bone marrow and produce large amounts of abnormal antibodies, leading to bone damage, anemia, and an increased risk of infection.

Solid tumors of the bone marrow are rare and include conditions such as chordomas, Ewing sarcomas, and osteosarcomas. These cancers originate in the bones themselves or in other tissues that support the bones, but they can also spread to the bone marrow.

Treatment for bone marrow neoplasms depends on the type and stage of cancer, as well as the patient's overall health. Treatment options may include chemotherapy, radiation therapy, stem cell transplantation, targeted therapy, or a combination of these approaches.

Neoplasms in adipose tissue refer to abnormal and excessive growths of cells that form tumors within the fatty connective tissue. These neoplasms can be benign or malignant (cancerous). Benign neoplasms, such as lipomas, are slow-growing and typically do not spread to other parts of the body. Malignant neoplasms, on the other hand, are cancerous and can invade surrounding tissues and spread to distant sites in the body (metastasis). An example of a malignant neoplasm in adipose tissue is liposarcoma. It's important to note that while some neoplasms may not cause any symptoms, others can cause pain, swelling or other uncomfortable sensations, and therefore should be evaluated by a medical professional for proper diagnosis and treatment.

Colorectal neoplasms refer to abnormal growths in the colon or rectum, which can be benign or malignant. These growths can arise from the inner lining (mucosa) of the colon or rectum and can take various forms such as polyps, adenomas, or carcinomas.

Benign neoplasms, such as hyperplastic polyps and inflammatory polyps, are not cancerous but may need to be removed to prevent the development of malignant tumors. Adenomas, on the other hand, are precancerous lesions that can develop into colorectal cancer if left untreated.

Colorectal cancer is a malignant neoplasm that arises from the uncontrolled growth and division of cells in the colon or rectum. It is one of the most common types of cancer worldwide and can spread to other parts of the body through the bloodstream or lymphatic system.

Regular screening for colorectal neoplasms is recommended for individuals over the age of 50, as early detection and removal of precancerous lesions can significantly reduce the risk of developing colorectal cancer.

Meningeal neoplasms, also known as malignant meningitis or leptomeningeal carcinomatosis, refer to cancerous tumors that originate in the meninges, which are the membranes covering the brain and spinal cord. These tumors can arise primarily from the meningeal cells themselves, although they more commonly result from the spread (metastasis) of cancer cells from other parts of the body, such as breast, lung, or melanoma.

Meningeal neoplasms can cause a variety of symptoms, including headaches, nausea and vomiting, mental status changes, seizures, and focal neurological deficits. Diagnosis typically involves imaging studies (such as MRI) and analysis of cerebrospinal fluid obtained through a spinal tap. Treatment options may include radiation therapy, chemotherapy, or surgery, depending on the type and extent of the tumor. The prognosis for patients with meningeal neoplasms is generally poor, with a median survival time of several months to a year.

Duodenal neoplasms refer to abnormal growths in the duodenum, which is the first part of the small intestine that receives digestive secretions from the pancreas and bile duct. These growths can be benign or malignant (cancerous).

Benign neoplasms include adenomas, leiomyomas, lipomas, and hamartomas. They are usually slow-growing and do not spread to other parts of the body. However, they may cause symptoms such as abdominal pain, bleeding, or obstruction of the intestine.

Malignant neoplasms include adenocarcinomas, neuroendocrine tumors (carcinoids), lymphomas, and sarcomas. They are more aggressive and can invade surrounding tissues and spread to other parts of the body. Symptoms may include abdominal pain, weight loss, jaundice, anemia, or bowel obstruction.

The diagnosis of duodenal neoplasms is usually made through imaging tests such as CT scans, MRI, or endoscopy with biopsy. Treatment depends on the type and stage of the tumor and may include surgery, chemotherapy, radiation therapy, or a combination of these modalities.

Adrenal cortex neoplasms refer to abnormal growths (tumors) in the adrenal gland's outer layer, known as the adrenal cortex. These neoplasms can be benign or malignant (cancerous). Benign tumors are called adrenal adenomas, while cancerous tumors are called adrenocortical carcinomas.

Adrenal cortex neoplasms can produce various hormones, leading to different clinical presentations. For instance, they may cause Cushing's syndrome (characterized by excessive cortisol production), Conn's syndrome (caused by aldosterone excess), or virilization (due to androgen excess). Some tumors may not produce any hormones and are discovered incidentally during imaging studies for unrelated conditions.

The diagnosis of adrenal cortex neoplasms typically involves a combination of imaging techniques, such as CT or MRI scans, and hormonal assessments to determine if the tumor is functional or non-functional. In some cases, a biopsy may be necessary to confirm the diagnosis and differentiate between benign and malignant tumors. Treatment options depend on the type, size, location, and hormonal activity of the neoplasm and may include surgical excision, radiation therapy, chemotherapy, or a combination of these approaches.

A mouth neoplasm refers to an abnormal growth or tumor in the oral cavity, which can be benign (non-cancerous) or malignant (cancerous). Malignant mouth neoplasms are also known as oral cancer. They can develop on the lips, gums, tongue, roof and floor of the mouth, inside the cheeks, and in the oropharynx (the middle part of the throat at the back of the mouth).

Mouth neoplasms can have various causes, including genetic factors, tobacco use, alcohol consumption, and infection with human papillomavirus (HPV). Symptoms may include a lump or thickening in the oral soft tissues, white or red patches, persistent mouth sores, difficulty swallowing or speaking, and numbness in the mouth. Early detection and treatment of mouth neoplasms are crucial for improving outcomes and preventing complications.

Mediastinal neoplasms refer to abnormal growths or tumors located in the mediastinum, which is the central compartment of the thoracic cavity that lies between the lungs and contains various vital structures such as the heart, esophagus, trachea, blood vessels, lymph nodes, and nerves. Mediastinal neoplasms can be benign (non-cancerous) or malignant (cancerous), and they can arise from any of the tissues or organs within the mediastinum.

Benign mediastinal neoplasms may include thymomas, lipomas, neurofibromas, or teratomas, among others. These tumors are typically slow-growing and rarely spread to other parts of the body. However, they can still cause symptoms or complications by compressing adjacent structures within the mediastinum, such as the airways, blood vessels, or nerves.

Malignant mediastinal neoplasms are cancerous tumors that can invade and destroy surrounding tissues and may spread (metastasize) to other parts of the body. Common types of malignant mediastinal neoplasms include thymic carcinomas, lymphomas, germ cell tumors, and neuroendocrine tumors. These tumors often require aggressive treatment, such as surgery, radiation therapy, and chemotherapy, to control their growth and spread.

It is important to note that mediastinal neoplasms can present with various symptoms depending on their location, size, and type. Some patients may be asymptomatic, while others may experience cough, chest pain, difficulty breathing, hoarseness, or swallowing difficulties. A thorough diagnostic workup, including imaging studies and biopsies, is necessary to confirm the diagnosis and determine the best course of treatment for mediastinal neoplasms.

Tongue neoplasms refer to abnormal growths or tumors that develop in the tongue tissue. These growths can be benign (non-cancerous) or malignant (cancerous).

Benign tongue neoplasms may include entities such as papillomas, fibromas, or granular cell tumors. They are typically slow growing and less likely to spread to other parts of the body.

Malignant tongue neoplasms, on the other hand, are cancers that can invade surrounding tissues and spread to other parts of the body. The most common type of malignant tongue neoplasm is squamous cell carcinoma, which arises from the thin, flat cells (squamous cells) that line the surface of the tongue.

Tongue neoplasms can cause various symptoms such as a lump or thickening on the tongue, pain or burning sensation in the mouth, difficulty swallowing or speaking, and unexplained bleeding from the mouth. Early detection and treatment are crucial for improving outcomes and preventing complications.

Ileal neoplasms refer to abnormal growths in the ileum, which is the final portion of the small intestine. These growths can be benign or malignant (cancerous). Common types of ileal neoplasms include:

1. Adenomas: These are benign tumors that can develop in the ileum and have the potential to become cancerous over time if not removed.
2. Carcinoids: These are slow-growing neuroendocrine tumors that typically start in the ileum. They can produce hormones that cause symptoms such as diarrhea, flushing, and heart problems.
3. Adenocarcinomas: These are malignant tumors that develop from the glandular cells lining the ileum. They are relatively rare but can be aggressive and require prompt treatment.
4. Lymphomas: These are cancers that start in the immune system cells found in the ileum's lining. They can cause symptoms such as abdominal pain, diarrhea, and weight loss.
5. Gastrointestinal stromal tumors (GISTs): These are rare tumors that develop from the connective tissue of the ileum's wall. While most GISTs are benign, some can be malignant and require treatment.

It is important to note that early detection and treatment of ileal neoplasms can significantly improve outcomes and prognosis. Regular screenings and check-ups with a healthcare provider are recommended for individuals at higher risk for developing these growths.

Stomach neoplasms refer to abnormal growths in the stomach that can be benign or malignant. They include a wide range of conditions such as:

1. Gastric adenomas: These are benign tumors that develop from glandular cells in the stomach lining.
2. Gastrointestinal stromal tumors (GISTs): These are rare tumors that can be found in the stomach and other parts of the digestive tract. They originate from the stem cells in the wall of the digestive tract.
3. Leiomyomas: These are benign tumors that develop from smooth muscle cells in the stomach wall.
4. Lipomas: These are benign tumors that develop from fat cells in the stomach wall.
5. Neuroendocrine tumors (NETs): These are tumors that develop from the neuroendocrine cells in the stomach lining. They can be benign or malignant.
6. Gastric carcinomas: These are malignant tumors that develop from the glandular cells in the stomach lining. They are the most common type of stomach neoplasm and include adenocarcinomas, signet ring cell carcinomas, and others.
7. Lymphomas: These are malignant tumors that develop from the immune cells in the stomach wall.

Stomach neoplasms can cause various symptoms such as abdominal pain, nausea, vomiting, weight loss, and difficulty swallowing. The diagnosis of stomach neoplasms usually involves a combination of imaging tests, endoscopy, and biopsy. Treatment options depend on the type and stage of the neoplasm and may include surgery, chemotherapy, radiation therapy, or targeted therapy.

Urinary Bladder Neoplasms are abnormal growths or tumors in the urinary bladder, which can be benign (non-cancerous) or malignant (cancerous). Malignant neoplasms can be further classified into various types of bladder cancer, such as urothelial carcinoma, squamous cell carcinoma, and adenocarcinoma. These malignant tumors often invade surrounding tissues and organs, potentially spreading to other parts of the body (metastasis), which can lead to serious health consequences if not detected and treated promptly and effectively.

Carcinoma, acinar cell is a type of pancreatic cancer that originates in the acinar cells of the pancreas. The acinar cells are responsible for producing digestive enzymes. This type of cancer is relatively rare and accounts for less than 5% of all pancreatic cancers. It typically presents with symptoms such as abdominal pain, weight loss, and jaundice. Treatment options may include surgery, chemotherapy, and radiation therapy.

Spinal cord neoplasms refer to abnormal growths or tumors within the spinal cord. These can be benign (non-cancerous) or malignant (cancerous). They originate from the cells within the spinal cord itself (primary tumors), or they may spread to the spinal cord from other parts of the body (metastatic tumors). Spinal cord neoplasms can cause various symptoms depending on their location and size, including back pain, neurological deficits, and even paralysis. Treatment options include surgery, radiation therapy, and chemotherapy.

Vaginal neoplasms refer to abnormal growths or tumors in the vagina. These growths can be benign (non-cancerous) or malignant (cancerous). The two main types of vaginal neoplasms are:

1. Vaginal intraepithelial neoplasia (VAIN): This is a condition where the cells on the inner lining of the vagina become abnormal but have not invaded deeper tissues. VAIN can be low-grade or high-grade, depending on the severity of the cell changes.
2. Vaginal cancer: This is a malignant tumor that arises from the cells in the vagina. The two main types of vaginal cancer are squamous cell carcinoma and adenocarcinoma. Squamous cell carcinoma is the most common type, accounting for about 85% of all cases.

Risk factors for vaginal neoplasms include human papillomavirus (HPV) infection, smoking, older age, history of cervical cancer or precancerous changes, and exposure to diethylstilbestrol (DES) in utero. Treatment options depend on the type, stage, and location of the neoplasm but may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

An oxyphilic adenoma is a type of benign tumor that develops in the endocrine glands, specifically in the parathyroid gland. This type of adenoma is characterized by the presence of cells called oxyphils, which have an abundance of mitochondria and appear pink on histological examination due to their high oxidative enzyme activity. Oxyphilic adenomas are a common cause of primary hyperparathyroidism, a condition in which the parathyroid glands produce too much parathyroid hormone (PTH), leading to an imbalance of calcium and phosphorus metabolism. Symptoms of primary hyperparathyroidism may include fatigue, weakness, bone pain, kidney stones, and psychological disturbances. Treatment typically involves surgical removal of the affected parathyroid gland.

Local neoplasm recurrence is the return or regrowth of a tumor in the same location where it was originally removed or treated. This means that cancer cells have survived the initial treatment and started to grow again in the same area. It's essential to monitor and detect any local recurrence as early as possible, as it can affect the prognosis and may require additional treatment.

Nervous system neoplasms are abnormal growths or tumors that occur within the nervous system, which includes the brain, spinal cord, and peripheral nerves. These tumors can be benign (non-cancerous) or malignant (cancerous), and their growth can compress or infiltrate surrounding tissues, leading to various neurological symptoms. The causes of nervous system neoplasms are not fully understood but may involve genetic factors, exposure to certain chemicals or radiation, and certain viral infections. Treatment options depend on the type, location, and size of the tumor and can include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Janus Kinase 2 (JAK2) is a tyrosine kinase enzyme that plays a crucial role in intracellular signal transduction. It is named after the Roman god Janus, who is depicted with two faces, as JAK2 has two similar phosphate-transferring domains. JAK2 is involved in various cytokine receptor-mediated signaling pathways and contributes to hematopoiesis, immune function, and cell growth.

Mutations in the JAK2 gene have been associated with several myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. The most common mutation is JAK2 V617F, which results in a constitutively active enzyme that promotes uncontrolled cell proliferation and survival, contributing to the development of these MPNs.

Neoplasm metastasis is the spread of cancer cells from the primary site (where the original or primary tumor formed) to other places in the body. This happens when cancer cells break away from the original (primary) tumor and enter the bloodstream or lymphatic system. The cancer cells can then travel to other parts of the body and form new tumors, called secondary tumors or metastases.

Metastasis is a key feature of malignant neoplasms (cancers), and it is one of the main ways that cancer can cause harm in the body. The metastatic tumors may continue to grow and may cause damage to the organs and tissues where they are located. They can also release additional cancer cells into the bloodstream or lymphatic system, leading to further spread of the cancer.

The metastatic tumors are named based on the location where they are found, as well as the type of primary cancer. For example, if a patient has a primary lung cancer that has metastasized to the liver, the metastatic tumor would be called a liver metastasis from lung cancer.

It is important to note that the presence of metastases can significantly affect a person's prognosis and treatment options. In general, metastatic cancer is more difficult to treat than cancer that has not spread beyond its original site. However, there are many factors that can influence a person's prognosis and response to treatment, so it is important for each individual to discuss their specific situation with their healthcare team.

Muscle neoplasms are abnormal growths or tumors that develop in the muscle tissue. They can be benign (non-cancerous) or malignant (cancerous). Benign muscle neoplasms are typically slow-growing and do not spread to other parts of the body, while malignant muscle neoplasms, also known as soft tissue sarcomas, can grow quickly, invade nearby tissues, and metastasize (spread) to distant parts of the body.

Soft tissue sarcomas can arise from any of the muscles in the body, including the skeletal muscles (voluntary muscles that attach to bones and help with movement), smooth muscles (involuntary muscles found in the walls of blood vessels, digestive tract, and other organs), or cardiac muscle (the specialized muscle found in the heart).

There are many different types of soft tissue sarcomas, each with its own set of characteristics and prognosis. Treatment for muscle neoplasms typically involves a combination of surgery, radiation therapy, and chemotherapy, depending on the type, size, location, and stage of the tumor.

Experimental liver neoplasms refer to abnormal growths or tumors in the liver that are intentionally created or manipulated in a laboratory setting for the purpose of studying their development, progression, and potential treatment options. These experimental models can be established using various methods such as chemical induction, genetic modification, or transplantation of cancerous cells or tissues. The goal of this research is to advance our understanding of liver cancer biology and develop novel therapies for liver neoplasms in humans. It's important to note that these experiments are conducted under strict ethical guidelines and regulations to minimize harm and ensure the humane treatment of animals involved in such studies.

Hemangiosarcoma is a type of cancer that arises from the cells that line the blood vessels (endothelial cells). It most commonly affects middle-aged to older dogs, but it can also occur in cats and other animals, as well as rarely in humans.

This cancer can develop in various parts of the body, including the skin, heart, spleen, liver, and lungs. Hemangiosarcomas of the skin tend to be more benign and have a better prognosis than those that arise internally.

Hemangiosarcomas are highly invasive and often metastasize (spread) to other organs, making them difficult to treat. The exact cause of hemangiosarcoma is not known, but exposure to certain chemicals, radiation, and viruses may increase the risk of developing this cancer. Treatment options typically include surgery, chemotherapy, and/or radiation therapy, depending on the location and stage of the tumor.

Carcinoma is a type of cancer that develops from epithelial cells, which are the cells that line the inner and outer surfaces of the body. These cells cover organs, glands, and other structures within the body. Carcinomas can occur in various parts of the body, including the skin, lungs, breasts, prostate, colon, and pancreas. They are often characterized by the uncontrolled growth and division of abnormal cells that can invade surrounding tissues and spread to other parts of the body through a process called metastasis. Carcinomas can be further classified based on their appearance under a microscope, such as adenocarcinoma, squamous cell carcinoma, and basal cell carcinoma.

Adenocarcinoma is a type of cancer that arises from glandular epithelial cells. These cells line the inside of many internal organs, including the breasts, prostate, colon, and lungs. Adenocarcinomas can occur in any of these organs, as well as in other locations where glands are present.

The term "adenocarcinoma" is used to describe a cancer that has features of glandular tissue, such as mucus-secreting cells or cells that produce hormones. These cancers often form glandular structures within the tumor mass and may produce mucus or other substances.

Adenocarcinomas are typically slow-growing and tend to spread (metastasize) to other parts of the body through the lymphatic system or bloodstream. They can be treated with surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these treatments. The prognosis for adenocarcinoma depends on several factors, including the location and stage of the cancer, as well as the patient's overall health and age.

Myelodysplastic-myeloproliferative diseases (MDS/MPD) are a group of rare and complex bone marrow disorders that exhibit features of both myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). MDS is characterized by ineffective hematopoiesis, leading to cytopenias, and dysplastic changes in the bone marrow. MPNs are clonal disorders of the hematopoietic stem cells resulting in increased proliferation of one or more cell lines, often leading to elevated blood counts.

MDS/MPD share features of both these entities, with patients showing signs of both ineffective hematopoiesis and increased cell production. These disorders have overlapping clinical, laboratory, and morphological characteristics, making their classification challenging. The World Health Organization (WHO) has recognized several MDS/MPD subtypes, including chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), atypical chronic myeloid leukemia (aCML), and myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN, U).

The pathogenesis of MDS/MPD involves genetic mutations that affect various cellular processes, such as signal transduction, epigenetic regulation, and splicing machinery. The prognosis for patients with MDS/MPD varies depending on the specific subtype, age, performance status, and the presence of certain genetic abnormalities. Treatment options may include supportive care, chemotherapy, targeted therapy, or stem cell transplantation.

A pancreatectomy is a surgical procedure in which all or part of the pancreas is removed. There are several types of pancreatectomies, including:

* **Total pancreatectomy:** Removal of the entire pancreas, as well as the spleen and nearby lymph nodes. This type of pancreatectomy is usually done for patients with cancer that has spread throughout the pancreas or for those who have had multiple surgeries to remove pancreatic tumors.
* **Distal pancreatectomy:** Removal of the body and tail of the pancreas, as well as nearby lymph nodes. This type of pancreatectomy is often done for patients with tumors in the body or tail of the pancreas.
* **Partial (or segmental) pancreatectomy:** Removal of a portion of the head or body of the pancreas, as well as nearby lymph nodes. This type of pancreatectomy is often done for patients with tumors in the head or body of the pancreas that can be removed without removing the entire organ.
* **Pylorus-preserving pancreaticoduodenectomy (PPPD):** A type of surgery used to treat tumors in the head of the pancreas, as well as other conditions such as chronic pancreatitis. In this procedure, the head of the pancreas, duodenum, gallbladder, and bile duct are removed, but the stomach and lower portion of the esophagus (pylorus) are left in place.

After a pancreatectomy, patients may experience problems with digestion and blood sugar regulation, as the pancreas plays an important role in these functions. Patients may need to take enzyme supplements to help with digestion and may require insulin therapy to manage their blood sugar levels.

Peripheral nervous system (PNS) neoplasms refer to tumors that originate in the peripheral nerves, which are the nerves outside the brain and spinal cord. These tumors can be benign or malignant (cancerous). Benign tumors, such as schwannomas and neurofibromas, grow slowly and do not spread to other parts of the body. Malignant tumors, such as malignant peripheral nerve sheath tumors (MPNSTs), can invade nearby tissues and may metastasize (spread) to other organs.

PNS neoplasms can cause various symptoms depending on their location and size. Common symptoms include pain, weakness, numbness, or tingling in the affected area. In some cases, PNS neoplasms may not cause any symptoms until they become quite large. Treatment options for PNS neoplasms depend on several factors, including the type, size, and location of the tumor, as well as the patient's overall health. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Cerebral ventricle neoplasms refer to tumors that develop within the cerebral ventricles, which are fluid-filled spaces in the brain. These tumors can arise from various types of cells within the ventricular system, including the ependymal cells that line the ventricles, choroid plexus cells that produce cerebrospinal fluid, or other surrounding tissues.

Cerebral ventricle neoplasms can cause a variety of symptoms depending on their size and location, such as headaches, nausea, vomiting, vision changes, imbalance, weakness, or difficulty with mental tasks. The treatment options for these tumors may include surgical resection, radiation therapy, and chemotherapy, depending on the type and extent of the tumor. Regular follow-up care is essential to monitor for recurrence and manage any long-term effects of treatment.

Paranasal sinus neoplasms refer to abnormal growths or tumors that develop within the paranasal sinuses, which are air-filled cavities located inside the skull near the nasal cavity. These tumors can be benign (noncancerous) or malignant (cancerous), and they can arise from various types of tissue within the sinuses, such as the lining of the sinuses (mucosa), bone, or other soft tissues.

Paranasal sinus neoplasms can cause a variety of symptoms, including nasal congestion, nosebleeds, facial pain or numbness, and visual disturbances. The diagnosis of these tumors typically involves a combination of imaging studies (such as CT or MRI scans) and biopsy to determine the type and extent of the tumor. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches, depending on the specific type and stage of the neoplasm.

Pleural neoplasms refer to abnormal growths or tumors that develop in the pleura, which is the thin, double layered membrane that surrounds the lungs and lines the inside of the chest wall. These neoplasms can be benign (non-cancerous) or malignant (cancerous).

Malignant pleural neoplasms are often associated with lung cancer, mesothelioma, or metastasis from other types of cancer. They can cause symptoms such as chest pain, cough, shortness of breath, and weight loss. Diagnosis typically involves imaging tests like X-rays or CT scans, followed by biopsy to confirm the type of tumor. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Breast neoplasms refer to abnormal growths in the breast tissue that can be benign or malignant. Benign breast neoplasms are non-cancerous tumors or growths, while malignant breast neoplasms are cancerous tumors that can invade surrounding tissues and spread to other parts of the body.

Breast neoplasms can arise from different types of cells in the breast, including milk ducts, milk sacs (lobules), or connective tissue. The most common type of breast cancer is ductal carcinoma, which starts in the milk ducts and can spread to other parts of the breast and nearby structures.

Breast neoplasms are usually detected through screening methods such as mammography, ultrasound, or MRI, or through self-examination or clinical examination. Treatment options for breast neoplasms depend on several factors, including the type and stage of the tumor, the patient's age and overall health, and personal preferences. Treatment may include surgery, radiation therapy, chemotherapy, hormone therapy, or targeted therapy.

X-ray computed tomography (CT or CAT scan) is a medical imaging method that uses computer-processed combinations of many X-ray images taken from different angles to produce cross-sectional (tomographic) images (virtual "slices") of the body. These cross-sectional images can then be used to display detailed internal views of organs, bones, and soft tissues in the body.

The term "computed tomography" is used instead of "CT scan" or "CAT scan" because the machines take a series of X-ray measurements from different angles around the body and then use a computer to process these data to create detailed images of internal structures within the body.

CT scanning is a noninvasive, painless medical test that helps physicians diagnose and treat medical conditions. CT imaging provides detailed information about many types of tissue including lung, bone, soft tissue and blood vessels. CT examinations can be performed on every part of the body for a variety of reasons including diagnosis, surgical planning, and monitoring of therapeutic responses.

In computed tomography (CT), an X-ray source and detector rotate around the patient, measuring the X-ray attenuation at many different angles. A computer uses this data to construct a cross-sectional image by the process of reconstruction. This technique is called "tomography". The term "computed" refers to the use of a computer to reconstruct the images.

CT has become an important tool in medical imaging and diagnosis, allowing radiologists and other physicians to view detailed internal images of the body. It can help identify many different medical conditions including cancer, heart disease, lung nodules, liver tumors, and internal injuries from trauma. CT is also commonly used for guiding biopsies and other minimally invasive procedures.

In summary, X-ray computed tomography (CT or CAT scan) is a medical imaging technique that uses computer-processed combinations of many X-ray images taken from different angles to produce cross-sectional images of the body. It provides detailed internal views of organs, bones, and soft tissues in the body, allowing physicians to diagnose and treat medical conditions.

Common bile duct neoplasms refer to abnormal growths that can occur in the common bile duct, which is a tube that carries bile from the liver and gallbladder into the small intestine. These growths can be benign or malignant (cancerous).

Benign neoplasms of the common bile duct include papillomas, adenomas, and leiomyomas. Malignant neoplasms are typically adenocarcinomas, which arise from the glandular cells lining the duct. Other types of malignancies that can affect the common bile duct include cholangiocarcinoma, gallbladder carcinoma, and metastatic cancer from other sites.

Symptoms of common bile duct neoplasms may include jaundice (yellowing of the skin and eyes), abdominal pain, dark urine, and light-colored stools. Diagnosis may involve imaging tests such as CT scans or MRCP (magnetic resonance cholangiopancreatography) and biopsy to confirm the type of neoplasm. Treatment options depend on the type and stage of the neoplasm and may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Orbital neoplasms refer to abnormal growths or tumors that develop in the orbit, which is the bony cavity that contains the eyeball, muscles, nerves, fat, and blood vessels. These neoplasms can be benign (non-cancerous) or malignant (cancerous), and they can arise from various types of cells within the orbit.

Orbital neoplasms can cause a variety of symptoms depending on their size, location, and rate of growth. Common symptoms include protrusion or displacement of the eyeball, double vision, limited eye movement, pain, swelling, and numbness in the face. In some cases, orbital neoplasms may not cause any noticeable symptoms, especially if they are small and slow-growing.

There are many different types of orbital neoplasms, including:

1. Optic nerve glioma: a rare tumor that arises from the optic nerve's supportive tissue.
2. Orbital meningioma: a tumor that originates from the membranes covering the brain and extends into the orbit.
3. Lacrimal gland tumors: benign or malignant growths that develop in the lacrimal gland, which produces tears.
4. Orbital lymphangioma: a non-cancerous tumor that arises from the lymphatic vessels in the orbit.
5. Rhabdomyosarcoma: a malignant tumor that develops from the skeletal muscle cells in the orbit.
6. Metastatic tumors: cancerous growths that spread to the orbit from other parts of the body, such as the breast, lung, or prostate.

The diagnosis and treatment of orbital neoplasms depend on several factors, including the type, size, location, and extent of the tumor. Imaging tests, such as CT scans and MRI, are often used to visualize the tumor and determine its extent. A biopsy may also be performed to confirm the diagnosis and determine the tumor's type and grade. Treatment options include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Abdominal neoplasms refer to abnormal growths or tumors in the abdomen that can be benign (non-cancerous) or malignant (cancerous). These growths can occur in any of the organs within the abdominal cavity, including the stomach, small intestine, large intestine, liver, pancreas, spleen, and kidneys.

Abdominal neoplasms can cause various symptoms depending on their size, location, and type. Some common symptoms include abdominal pain or discomfort, bloating, changes in bowel habits, unexplained weight loss, fatigue, and fever. In some cases, abdominal neoplasms may not cause any symptoms until they have grown quite large or spread to other parts of the body.

The diagnosis of abdominal neoplasms typically involves a combination of physical exam, medical history, imaging studies such as CT scans or MRIs, and sometimes biopsy to confirm the type of tumor. Treatment options depend on the type, stage, and location of the neoplasm but may include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these approaches.

Cerebellar neoplasms refer to abnormal growths or tumors that develop in the cerebellum, which is the part of the brain responsible for coordinating muscle movements and maintaining balance. These tumors can be benign (non-cancerous) or malignant (cancerous), and they can arise from various types of cells within the cerebellum.

The most common type of cerebellar neoplasm is a medulloblastoma, which arises from primitive nerve cells in the cerebellum. Other types of cerebellar neoplasms include astrocytomas, ependymomas, and brain stem gliomas. Symptoms of cerebellar neoplasms may include headaches, vomiting, unsteady gait, coordination problems, and visual disturbances. Treatment options depend on the type, size, and location of the tumor, as well as the patient's overall health and age. Treatment may involve surgery, radiation therapy, chemotherapy, or a combination of these approaches.

A lipoma is a common, benign (non-cancerous) soft tissue growth. It is composed of adipose or fatty tissue and typically found just beneath the skin, but they can also occur deeper within the body. Lipomas are usually round, moveable, and painless, although they may cause discomfort if they grow large enough to put pressure on nearby nerves or if they're located in a sensitive area. They generally grow slowly over time. Surgical removal is an option if the lipoma becomes bothersome or grows significantly in size. It's important to note that while lipomas are typically harmless, any new lumps or bumps should be evaluated by a healthcare professional to confirm the diagnosis and rule out other more serious conditions.

Facial neoplasms refer to abnormal growths or tumors that develop in the tissues of the face. These growths can be benign (non-cancerous) or malignant (cancerous). Facial neoplasms can occur in any of the facial structures, including the skin, muscles, bones, nerves, and glands.

Benign facial neoplasms are typically slow-growing and do not spread to other parts of the body. Examples include papillomas, hemangiomas, and neurofibromas. While these tumors are usually harmless, they can cause cosmetic concerns or interfere with normal facial function.

Malignant facial neoplasms, on the other hand, can be aggressive and invasive. They can spread to other parts of the face, as well as to distant sites in the body. Common types of malignant facial neoplasms include basal cell carcinoma, squamous cell carcinoma, and melanoma.

Treatment for facial neoplasms depends on several factors, including the type, size, location, and stage of the tumor. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches. It is important to seek medical attention promptly if you notice any unusual growths or changes in the skin or tissues of your face.

Retrospective studies, also known as retrospective research or looking back studies, are a type of observational study that examines data from the past to draw conclusions about possible causal relationships between risk factors and outcomes. In these studies, researchers analyze existing records, medical charts, or previously collected data to test a hypothesis or answer a specific research question.

Retrospective studies can be useful for generating hypotheses and identifying trends, but they have limitations compared to prospective studies, which follow participants forward in time from exposure to outcome. Retrospective studies are subject to biases such as recall bias, selection bias, and information bias, which can affect the validity of the results. Therefore, retrospective studies should be interpreted with caution and used primarily to generate hypotheses for further testing in prospective studies.

"Neoplasms by site" refers to the classification and description of abnormal growths or tumors based on their location within the body. This term is often used in pathology reports, medical literature, and research to provide a more specific identification and understanding of the type of neoplasm, its behavior, and potential impact on the patient's health.

Neoplasms can develop in any organ or tissue in the body, and their growth patterns and characteristics may vary depending on the site. For example, a neoplasm arising in the lung will have different clinical symptoms, diagnostic approaches, treatment options, and prognosis compared to a neoplasm found in the breast or colon.

By specifying the site of the neoplasm, healthcare providers can make more informed decisions about diagnosis, staging, and treatment, as well as monitor potential recurrence or metastasis. Additionally, researchers can use this information to better understand the underlying causes and risk factors associated with specific types of neoplasms, which may lead to the development of new prevention strategies and treatments.

Bronchial neoplasms refer to abnormal growths or tumors in the bronchi, which are the large airways that lead into the lungs. These neoplasms can be benign (non-cancerous) or malignant (cancerous). Malignant bronchial neoplasms are often referred to as lung cancer and can be further classified into small cell lung cancer and non-small cell lung cancer, depending on the type of cells involved.

Benign bronchial neoplasms are less common than malignant ones and may include growths such as papillomas, hamartomas, or chondromas. While benign neoplasms are not cancerous, they can still cause symptoms and complications if they grow large enough to obstruct the airways or if they become infected.

Treatment for bronchial neoplasms depends on several factors, including the type, size, location, and stage of the tumor, as well as the patient's overall health and medical history. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Malignant histiocytic disorders are a group of rare and aggressive cancers that affect the mononuclear phagocyte system, which includes histiocytes or cells that originate from bone marrow precursors called monoblasts. These disorders are characterized by the uncontrolled proliferation of malignant histiocytes, leading to tissue invasion and damage.

There are several types of malignant histiocytic disorders, including:

1. Acute Monocytic Leukemia (AML-M5): This is a subtype of acute myeloid leukemia that affects the monocyte cell lineage and can involve the skin, lymph nodes, and other organs.
2. Langerhans Cell Histiocytosis (LCH): Although primarily considered a benign histiocytic disorder, some cases of LCH can progress to a malignant form with aggressive behavior and poor prognosis.
3. Malignant Histiocytosis (MH): This is a rare and aggressive disorder characterized by the infiltration of malignant histiocytes into various organs, including the liver, spleen, and lymph nodes.
4. Histiocytic Sarcoma (HS): This is a highly aggressive cancer that arises from malignant histiocytes and can affect various organs, such as the skin, lymph nodes, and soft tissues.

Symptoms of malignant histiocytic disorders depend on the type and extent of organ involvement but may include fever, fatigue, weight loss, anemia, and enlarged lymph nodes or organs. Treatment typically involves a combination of chemotherapy, radiation therapy, and/or stem cell transplantation. The prognosis for malignant histiocytic disorders is generally poor, with a high risk of relapse and a low overall survival rate.

Urogenital neoplasms refer to abnormal growths or tumors that occur in the urinary and genital organs. These can include various types of cancer, such as bladder cancer, kidney cancer, prostate cancer, testicular cancer, cervical cancer, ovarian cancer, and others. Some urogenital neoplasms may be benign (non-cancerous), while others are malignant (cancerous) and can spread to other parts of the body.

The term "urogenital" refers to the combined urinary and genital systems in the human body. The urinary system includes the kidneys, ureters, bladder, and urethra, which are responsible for filtering waste from the blood and eliminating it as urine. The genital system includes the reproductive organs such as the ovaries, fallopian tubes, uterus, vagina, prostate gland, testicles, and penis.

Urogenital neoplasms can cause various symptoms depending on their location and size. Common symptoms include blood in urine, pain during urination, difficulty urinating, abnormal discharge, lumps or swelling in the genital area, and unexplained weight loss. If you experience any of these symptoms, it is important to consult a healthcare professional for further evaluation and treatment.

Spinal neoplasms refer to abnormal growths or tumors found within the spinal column, which can be benign (non-cancerous) or malignant (cancerous). These tumors can originate in the spine itself, called primary spinal neoplasms, or they can spread to the spine from other parts of the body, known as secondary or metastatic spinal neoplasms. Spinal neoplasms can cause various symptoms, such as back pain, neurological deficits, and even paralysis, depending on their location and size. Early diagnosis and treatment are crucial to prevent or minimize long-term complications and improve the patient's prognosis.

Skull neoplasms refer to abnormal growths or tumors that develop within the skull. These growths can be benign (non-cancerous) or malignant (cancerous). They can originate from various types of cells, such as bone cells, nerve cells, or soft tissues. Skull neoplasms can cause various symptoms depending on their size and location, including headaches, seizures, vision problems, hearing loss, and neurological deficits. Treatment options include surgery, radiation therapy, and chemotherapy. It is important to note that a neoplasm in the skull can also refer to metastatic cancer, which has spread from another part of the body to the skull.

Vulvar neoplasms refer to abnormal growths or tumors in the vulvar region, which is the exterior female genital area including the mons pubis, labia majora, labia minora, clitoris, and the vaginal vestibule. These neoplasms can be benign (non-cancerous) or malignant (cancerous).

Benign vulvar neoplasms may include conditions such as vulvar cysts, fibromas, lipomas, or condylomas (genital warts). They are typically slow-growing and less likely to spread or invade surrounding tissues.

Malignant vulvar neoplasms, on the other hand, are cancers that can invade nearby tissues and potentially metastasize (spread) to distant parts of the body. The most common types of malignant vulvar neoplasms are squamous cell carcinoma, vulvar melanoma, and adenocarcinoma.

Early detection and treatment of vulvar neoplasms are essential for improving prognosis and reducing the risk of complications or recurrence. Regular gynecological examinations, self-examinations, and prompt attention to any unusual symptoms or changes in the vulvar area can help ensure timely diagnosis and management.

Neuroepithelial neoplasms are a type of tumor that arises from the neuroepithelium, which is the tissue in the developing embryo that gives rise to the nervous system. These tumors can occur anywhere along the nervous system, including the brain and spinal cord (central nervous system) or the peripheral nerves.

Neuroepithelial neoplasms can be benign or malignant, and they can vary widely in their behavior and prognosis. Some common types of neuroepithelial neoplasms include:

1. Astrocytomas: These are tumors that arise from astrocytes, a type of star-shaped glial cell in the brain. Astrocytomas can be low-grade (slow-growing) or high-grade (fast-growing), and they can occur in different parts of the brain.
2. Oligodendrogliomas: These are tumors that arise from oligodendrocytes, a type of glial cell that provides support and insulation to nerve cells in the brain. Oligodendrogliomas are typically low-grade and slow-growing.
3. Ependymomas: These are tumors that arise from the ependyma, which is the tissue that lines the ventricles (fluid-filled spaces) in the brain and the spinal cord canal. Ependymomas can be benign or malignant, and they can occur in the brain or the spinal cord.
4. Medulloblastomas: These are fast-growing tumors that arise from primitive neuroectodermal cells in the cerebellum (the part of the brain that controls balance and coordination). Medulloblastomas are highly malignant and can spread to other parts of the brain and spinal cord.
5. Glioblastomas: These are the most common and aggressive type of primary brain tumor. They arise from astrocytes and can grow rapidly, invading surrounding brain tissue.

Neuroepithelial neoplasms are typically treated with surgery, radiation therapy, and chemotherapy, depending on the type and location of the tumor. The prognosis varies widely depending on the specific type and stage of the tumor.

Ear neoplasms refer to abnormal growths or tumors that occur in the ear. These growths can be benign (non-cancerous) or malignant (cancerous) and can affect any part of the ear, including the outer ear, middle ear, inner ear, and the ear canal.

Benign ear neoplasms are typically slow-growing and do not spread to other parts of the body. Examples include exostoses, osteomas, and ceruminous adenomas. These types of growths are usually removed surgically for cosmetic reasons or if they cause discomfort or hearing problems.

Malignant ear neoplasms, on the other hand, can be aggressive and may spread to other parts of the body. Examples include squamous cell carcinoma, basal cell carcinoma, and adenoid cystic carcinoma. These types of tumors often require more extensive treatment, such as surgery, radiation therapy, and chemotherapy.

It is important to note that any new growth or change in the ear should be evaluated by a healthcare professional to determine the nature of the growth and develop an appropriate treatment plan.

Lip neoplasms refer to abnormal growths or tumors that occur in the lip tissue. These growths can be benign (non-cancerous) or malignant (cancerous). Benign lip neoplasms include conditions such as papillomas, fibromas, and mucocele, while malignant lip neoplasms are typically squamous cell carcinomas.

Squamous cell carcinoma of the lip is the most common type of lip cancer, accounting for about 90% of all lip cancers. It usually develops on the lower lip, and is often associated with prolonged sun exposure, smoking, and alcohol consumption. Symptoms may include a sore or lump on the lip that does not heal, bleeding, pain, numbness, or difficulty moving the lips.

It's important to note that any abnormal growth or change in the lips should be evaluated by a healthcare professional for proper diagnosis and treatment.

A fibroma is a benign (non-cancerous) tumor that consists primarily of fibrous or connective tissue. It can occur in various parts of the body, including the skin, mouth, and internal organs. The term "fibroma" is often used to describe any benign fibrous growth, but there are specific types of fibromas such as dermatofibroma (found in the skin), oral fibroma (found in the mouth), and benign fibrous histiocytoma (found in soft tissues).

It's important to note that while fibromas are generally harmless, they can cause discomfort or problems depending on their size and location. If a fibroma is causing issues or there's concern about its growth or malignancy, it should be evaluated by a healthcare professional for potential removal or further assessment.

Neoplasm transplantation is not a recognized or established medical procedure in the field of oncology. The term "neoplasm" refers to an abnormal growth of cells, which can be benign or malignant (cancerous). "Transplantation" typically refers to the surgical transfer of living cells, tissues, or organs from one part of the body to another or between individuals.

The concept of neoplasm transplantation may imply the transfer of cancerous cells or tissues from a donor to a recipient, which is not a standard practice due to ethical considerations and the potential harm it could cause to the recipient. In some rare instances, researchers might use laboratory animals to study the transmission and growth of human cancer cells, but this is done for scientific research purposes only and under strict regulatory guidelines.

In summary, there is no medical definition for 'Neoplasm Transplantation' as it does not represent a standard or ethical medical practice.

Adrenal gland neoplasms refer to abnormal growths or tumors in the adrenal glands. These glands are located on top of each kidney and are responsible for producing hormones that regulate various bodily functions such as metabolism, blood pressure, and stress response. Adrenal gland neoplasms can be benign (non-cancerous) or malignant (cancerous).

Benign adrenal tumors are called adenomas and are usually small and asymptomatic. However, some adenomas may produce excessive amounts of hormones, leading to symptoms such as high blood pressure, weight gain, and mood changes.

Malignant adrenal tumors are called adrenocortical carcinomas and are rare but aggressive cancers that can spread to other parts of the body. Symptoms of adrenocortical carcinoma may include abdominal pain, weight loss, and hormonal imbalances.

It is important to diagnose and treat adrenal gland neoplasms early to prevent complications and improve outcomes. Diagnostic tests may include imaging studies such as CT scans or MRIs, as well as hormone level testing and biopsy. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Pelvic neoplasms refer to abnormal growths or tumors located in the pelvic region. These growths can be benign (non-cancerous) or malignant (cancerous). They can originate from various tissues within the pelvis, including the reproductive organs (such as ovaries, uterus, cervix, vagina, and vulva in women; and prostate, testicles, and penis in men), the urinary system (kidneys, ureters, bladder, and urethra), the gastrointestinal tract (colon, rectum, and anus), as well as the muscles, nerves, blood vessels, and other connective tissues.

Malignant pelvic neoplasms can invade surrounding tissues and spread to distant parts of the body (metastasize). The symptoms of pelvic neoplasms may vary depending on their location, size, and type but often include abdominal or pelvic pain, bloating, changes in bowel or bladder habits, unusual vaginal bleeding or discharge, and unintentional weight loss. Early detection and prompt treatment are crucial for improving the prognosis of malignant pelvic neoplasms.

Gingival neoplasms refer to abnormal growths or tumors that occur in the gingiva, which are the part of the gums that surround the teeth. These growths can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms include conditions such as fibromas, papillomas, and hemangiomas, while malignant neoplasms are typically squamous cell carcinomas.

Gingival neoplasms can present with a variety of symptoms, including swelling, bleeding, pain, and loose teeth. They may also cause difficulty with chewing, speaking, or swallowing. The exact cause of these neoplasms is not always known, but risk factors include tobacco use, alcohol consumption, poor oral hygiene, and certain viral infections.

Diagnosis of gingival neoplasms typically involves a thorough clinical examination, including a dental exam and biopsy. Treatment options depend on the type and stage of the neoplasm, but may include surgery, radiation therapy, chemotherapy, or a combination of these approaches. Regular dental check-ups and good oral hygiene practices can help to detect gingival neoplasms at an early stage and improve treatment outcomes.

Gallbladder neoplasms refer to abnormal growths in the tissue of the gallbladder, which can be benign or malignant. Benign neoplasms are non-cancerous and typically do not spread to other parts of the body. Malignant neoplasms, also known as gallbladder cancer, can invade nearby tissues and organs and may metastasize (spread) to distant parts of the body. Gallbladder neoplasms can cause symptoms such as abdominal pain, jaundice, and nausea, but they are often asymptomatic until they have advanced to an advanced stage. The exact causes of gallbladder neoplasms are not fully understood, but risk factors include gallstones, chronic inflammation of the gallbladder, and certain inherited genetic conditions.

Neoplasm seeding, also known as tumor seeding or iatrogenic implantation, is a rare complication that can occur during surgical procedures. It refers to the accidental spread of cancer cells from the primary tumor site to other locations in the body, usually along the path of a surgical incision or via bodily fluids. This can result in new tumor growths (metastases) at these sites, which may complicate treatment and worsen the patient's prognosis.

Neoplasm seeding is more commonly associated with certain types of surgeries, such as those involving the liver, pancreas, or other organs with highly vascular tumors. It can also occur during biopsy procedures, where a needle is used to remove tissue samples for diagnostic purposes. While neoplasm seeding is a known risk of these procedures, it is relatively uncommon and often outweighed by the benefits of timely and effective treatment.

Fibroepithelial neoplasms are benign (non-cancerous) growths that consist of both fibrous and epithelial tissue. These types of neoplasms can occur in various parts of the body, but they are most commonly found in the skin and mucous membranes. A well-known example of a fibroepithelial neoplasm is a skin tag (acrochordon). Other examples include fibroma, papilloma, and neurofibroma.

Fibroepithelial neoplasms are typically slow-growing and cause little to no discomfort or symptoms. However, they may be removed for cosmetic reasons or if they become irritated, inflamed, or start to bleed. In rare cases, a fibroepithelial neoplasm can undergo malignant transformation and develop into cancer. It is essential to have any new or changing growths evaluated by a healthcare professional to determine the appropriate course of action.

A fatal outcome is a term used in medical context to describe a situation where a disease, injury, or illness results in the death of an individual. It is the most severe and unfortunate possible outcome of any medical condition, and is often used as a measure of the severity and prognosis of various diseases and injuries. In clinical trials and research, fatal outcome may be used as an endpoint to evaluate the effectiveness and safety of different treatments or interventions.

Respiratory tract neoplasms refer to abnormal growths or tumors that occur in the respiratory system, which includes the nose, throat (pharynx), voice box (larynx), windpipe (trachea), bronchi, and lungs. These growths can be benign or malignant (cancerous). Malignant neoplasms are cancerous tumors that can invade nearby tissues, spread to other parts of the body, and interfere with normal respiratory function, leading to serious health consequences.

Respiratory tract neoplasms can have various causes, including genetic factors, exposure to environmental carcinogens such as tobacco smoke, asbestos, and radon, and certain viral infections. Symptoms of respiratory tract neoplasms may include coughing, wheezing, shortness of breath, chest pain, hoarseness, or blood in the sputum. Diagnosis typically involves imaging tests such as X-rays, CT scans, or PET scans, as well as biopsies to determine the type and extent of the tumor. Treatment options may include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these approaches.

Neoplasms of connective tissue are abnormal growths or tumors that develop from the cells that form the body's supportive framework, including bones, cartilage, tendons, ligaments, and other connective tissues. These neoplasms can be benign (non-cancerous) or malignant (cancerous), and they can cause various symptoms depending on their location and size.

There are several types of connective tissue neoplasms, including:

1. Fibroma: A benign tumor that arises from fibrous connective tissue.
2. Fibrosarcoma: A malignant tumor that develops from fibrous connective tissue.
3. Lipoma: A benign tumor that arises from fat cells.
4. Liposarcoma: A malignant tumor that develops from fat cells.
5. Chondroma: A benign tumor that arises from cartilage.
6. Chondrosarcoma: A malignant tumor that develops from cartilage.
7. Osteoma: A benign tumor that arises from bone.
8. Osteosarcoma: A malignant tumor that develops from bone.
9. Giant cell tumors: Benign or malignant tumors that contain many giant cells, which are large, multinucleated cells.
10. Synovial sarcoma: A malignant tumor that arises from the synovial tissue that lines joints and tendons.

Connective tissue neoplasms can cause various symptoms depending on their location and size. For example, a benign lipoma may cause a painless lump under the skin, while a malignant osteosarcoma may cause bone pain, swelling, and fractures. Treatment options for connective tissue neoplasms include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Neuroendocrine tumors (NETs) are a diverse group of neoplasms that arise from cells of the neuroendocrine system, which is composed of dispersed neuroendocrine cells throughout the body, often in close association with nerves and blood vessels. These cells have the ability to produce and secrete hormones or hormone-like substances in response to various stimuli. NETs can occur in a variety of organs, including the lungs, pancreas, small intestine, colon, rectum, stomach, and thyroid gland, as well as in some less common sites such as the thymus, adrenal glands, and nervous system.

NETs can be functional or nonfunctional, depending on whether they produce and secrete hormones or hormone-like substances that cause specific symptoms related to hormonal excess. Functional NETs may give rise to a variety of clinical syndromes, such as carcinoid syndrome, Zollinger-Ellison syndrome, pancreatic neuroendocrine tumor syndrome (also known as Verner-Morrison or WDHA syndrome), and others. Nonfunctional NETs are more likely to present with symptoms related to the size and location of the tumor, such as abdominal pain, intestinal obstruction, or bleeding.

The diagnosis of NETs typically involves a combination of imaging studies, biochemical tests (e.g., measurement of serum hormone levels), and histopathological examination of tissue samples obtained through biopsy or surgical resection. Treatment options depend on the type, location, stage, and grade of the tumor, as well as the presence or absence of functional symptoms. They may include surgery, radiation therapy, chemotherapy, targeted therapy, and/or peptide receptor radionuclide therapy (PRRT).

Neoplasm grading is a system used by pathologists to classify the degree of abnormality in cells that make up a tumor (neoplasm). It provides an assessment of how quickly the tumor is likely to grow and spread. The grade helps doctors predict the prognosis and determine the best treatment options.

Neoplasm grading typically involves evaluating certain cellular features under a microscope, such as:

1. Differentiation or degree of maturity: This refers to how closely the tumor cells resemble their normal counterparts in terms of size, shape, and organization. Well-differentiated tumors have cells that look more like normal cells and are usually slower growing. Poorly differentiated tumors have cells that appear very abnormal and tend to grow and spread more aggressively.

2. Mitotic count: This is the number of times the tumor cells divide (mitosis) within a given area. A higher mitotic count indicates a faster-growing tumor.

3. Necrosis: This refers to areas of dead tissue within the tumor. A significant amount of necrosis may suggest a more aggressive tumor.

Based on these and other factors, pathologists assign a grade to the tumor using a standardized system, such as the Bloom-Richardson or Scarff-Bloom-Richardson grading systems for breast cancer or the Fuhrman grading system for kidney cancer. The grade usually consists of a number or a range (e.g., G1, G2, G3, or G4) or a combination of grades (e.g., low grade, intermediate grade, and high grade).

In general, higher-grade tumors have a worse prognosis than lower-grade tumors because they are more likely to grow quickly, invade surrounding tissues, and metastasize (spread) to other parts of the body. However, neoplasm grading is just one aspect of cancer diagnosis and treatment planning. Other factors, such as the stage of the disease, location of the tumor, patient's overall health, and specific molecular markers, are also considered when making treatment decisions.

"Peritoneal Dissemination Complicating Morcellation of Uterine Mesenchymal Neoplasms". PLOS ONE. 7 (11): e50058. Bibcode: ...
"Peritoneal Dissemination Complicating Morcellation of Uterine Mesenchymal Neoplasms". PLOS ONE. 7 (11): e50058. Bibcode: ...
... ovarian neoplasms (malignant or benign), and peritoneal effusions. Atypical mesothelial hyperplasia Herbert, Ronald A.; ... Peritoneal mesothelial hyperplasia can be encountered in inflammatory pelvic disease with tubo-ovarian abscess, ... Mesothelial hyperplasia is usually an incidental finding during peritoneal examination during laparotomy or laparoscopy. ...
... peritoneal neoplasms MeSH C04.588.322.078 - adrenal gland neoplasms MeSH C04.588.322.078.265 - adrenal cortex neoplasms MeSH ... peritoneal neoplasms MeSH C04.588.033.731 - retroperitoneal neoplasms MeSH C04.588.149.030 - adamantinoma MeSH C04.588.149.276 ... skull base neoplasms MeSH C04.588.149.828 - spinal neoplasms MeSH C04.588.180.260 - breast neoplasms, male MeSH C04.588.180.390 ... bile duct neoplasms MeSH C04.588.274.120.250.250 - common bile duct neoplasms MeSH C04.588.274.120.401 - gallbladder neoplasms ...
... gastric peritoneal carcinomatosis, malignant peritoneal mesothelioma, or disseminated mucinous neoplasm of the appendix. These ... fallopian tube or primary peritoneal carcinoma, recurrent ovarian cancer, peritoneal colorectal carcinomatosis, ... In this procedure, warmed anti-cancer medications are infused and circulated in the peritoneal cavity (abdomen) for a short ... which may include the removal of all involved peritoneal areas. Evidence supports a benefit in certain cases of ovarian cancer ...
... increased risk of infection of PEG site Intra-abdominal malignancy with peritoneal involvement (tumor seeding into formed ... difficulties in locating stomach position by digital indentation of stomach and transillumination Gastric wall neoplasm ...
Retroperitoneal fibrosis Retroperitoneal lymph node dissection It is also possible to have a neoplasm in this area, more ... Examples of tumors include Primary peritoneal carcinoma Pseudomyxoma peritonei Examples of sarcomas include: Soft-tissue ... commonly a metastasis; or very rarely a primary neoplasm. The most common type is a sarcoma followed by lymphoma, extragonadal ...
Intraocular, into the eye, e.g., some medications for glaucoma or eye neoplasms. Intraosseous infusion (into the bone marrow) ... Intraperitoneal, (infusion or injection into the peritoneum) e.g. peritoneal dialysis. Intrathecal (into the spinal canal) is ...
Bleeding due to rupture of an intra-abdominal neoplasm, (e.g., Hepatoblastoma) Disseminated intravascular coagulation People on ... Hemoperitoneum (also haemoperitoneum, sometimes also hematoperitoneum) is the presence of blood in the peritoneal cavity. The ... Paracentesis or diagnostic peritoneal lavage Computed tomography Diagnostic laparoscopy or exploratory laparotomy Initial ... was an indication for emergency surgery to locate the source of bleeding and also to recover spilled blood from the peritoneal ...
They are common neoplasms with a strong tendency to occur bilaterally, and they account for approximately a quarter of all ... Serous carcinomas often have bulky peritoneal and omental metastases, and spread to the lymph nodes is frequent. Beginning in ... A serous tumour is a neoplasm that typically has papillary to solid formations of tumor cells with crowded nuclei, and which ... Rarely, serous tumors arise from other parts of the peritoneum, including serous primary peritoneal carcinomas. Even more ...
A subcategory of D48.1, Neoplasm of uncertain behavior of connective and other soft tissue, has been created with more specific ... peritoneal, retroperitoneal D48.115: Desmoid tumor of upper extremity and shoulder girdle D48.116: Desmoid tumor of lower ... Connective and soft tissue neoplasms, Rare diseases). ...
This lymphoma also belongs to a group of lymphoid neoplasms with plasmablastic differentiation that involve malignant ... or peritoneal cavities, without forming a contiguous tumor mass. In rare cases of these cavitary forms of PEL, the effusions ... List of hematologic conditions Chen BJ, Chuang SS (March 2020). "Lymphoid Neoplasms With Plasmablastic Differentiation: A ... peritoneal cavity (e.g. abdominal swelling), or, much less often, joints (e.g. swelling), the epidural space (e.g. central ...
The presence of multiloculation suggests a neoplasm, although the thin septation implies that the neoplasm is benign. For any ... For peritoneal inclusion cysts, which have a crumpled tissue-paper appearance and tend to follow the contour of adjacent organs ...
If the vaginal process fails to obliterate, the communication between the peritoneal cavity and scrotum persists after birth, ... neoplasm, or trauma). The tunica vaginalis is derived from the vaginal process of the peritoneum, which in the fetus precedes ...
... sebaceous gland neoplasms MeSH C17.800.882.743 - sweat gland neoplasms MeSH C17.800.893.592 - leg ulcer MeSH C17.800.893.592. ... peritoneal MeSH C17.300.775.099 - arthritis, rheumatoid MeSH C17.300.775.099.114 - arthritis, juvenile rheumatoid MeSH C17.300. ... breast neoplasms MeSH C17.800.090.500.260 - breast neoplasms, male MeSH C17.800.090.500.390 - carcinoma, ductal, breast MeSH ... sweat gland neoplasms The list continues at List of MeSH codes (C18). (Wikipedia articles in need of updating from February ...
... began to study the phenomenon of neoplasms in plants. Building on early grafting studies in plants as well as work by other ... bacterial RNA was demonstrated in frog brain cells after a bacterial peritoneal infection. In the April 1973 issue of the ...
Viral infections Rotavirus Norovirus Astrovirus Adenovirus Calicivirus Neoplasms (cancers) Adenocarcinoma Carcinoid ... ulcers Gastrointestinal perforation Hyperthyroidism Diverticulitis Radiation enterocolitis Mesenteric cysts Peritoneal ...
Also, peritoneal washings are taken, the omentum is removed, and pelvic and paraaortic lymph nodes are sampled. Staging at the ... Rarer forms of tubal neoplasm include leiomyosarcoma, and transitional cell carcinoma. As the tumor is often enmeshed with the ... Primary fallopian tube cancer (PFTC), often just tubal cancer, is a malignant neoplasm that originates from the fallopian tube ...
On the contrary, in some neoplasms CD44 upregulation is associated with a favorable outcome. This is true of prostate cancer, ... and increased adherence to peritoneal cells. CD44 variant isoforms are also relevant to the progression of head and neck ... and CD44-soluble proteins markedly reduces the malignant activities of various neoplasms, stressing the therapeutic potential ... "Menstrual endometrial cells from women with endometriosis demonstrate increased adherence to peritoneal cells and increased ...
This peritoneal tissue is known as the processus vaginalis. Normally, the communication between the processus vaginalis and the ... A secondary hydrocele is secondary to either inflammation or a neoplasm in the testis. A hydrocele testis usually occurs on one ...
Oei, T. N.; Jagannathan, J. P.; Ramaiya, N.; Ros, P. R. (2010). "Peritoneal Sarcomatosis Versus Peritoneal Carcinomatosis: ... Young, Robert H. (2004). "Pseudomyxoma peritonei and selected other aspects of the spread of appendiceal neoplasms". Seminars ... Fluid can be serous as seen in primary peritoneal carcinoma or mucinous such as found in pseudomyxoma peritonei which is ... Fluid produced by the cells can produce ascites which is typical in carcinomatosis, but less common in peritoneal sarcomatosis ...
Primary peritoneal carcinomas develop from the peritoneum, a membrane that covers the abdominal cavity that has the same ... They can develop further into a variety of other neoplasms, including choriocarcinoma, yolk sac tumor, and teratoma. They occur ... Rarely, teratomas can cause growing teratoma syndrome or peritoneal gliomatosis. Some experience menometrorrhagia and abnormal ... peritoneal tuberculosis, or paraovarian cyst. Ovaries that can be felt are also a sign of ovarian cancer in postmenopausal ...
A rare neoplasm, 95% cases occur in women, especially at the mean age of 45. Biliary cystadenoma and cystadenocarcinoma ... Ovary-ovarian mucinous cystadenoma Pancreas-pancreatic mucinous cystadenoma Peritoneum-peritoneal mucinous cystadenoma Liver- ... Both are multiloculated cystic neoplasms and are lined by a single layer of tall columnar cells with a clear basal nucleus and ... Pancreatic mucinous cystadenoma or mucinous cystadenoma of the pancreas (MCN) are a type of mucinous cystic neoplasm of the ...
More than 1500 different disorders of the skin exist, including cutaneous eruptions ("rashes") and neoplasms. Therefore, ... peritoneal, pleural, and cerebrospinal), and a wide range of other body sites. Cytopathology is generally used on samples of ...
Muzii L, Sereni MI, Battista C, Zullo MA, Tambone V, Angioli R (2010). "[Tubo-peritoneal factor of infertility: diagnosis and ... malignant neoplasms, acute renal failure, age under 18 years (no clinical study data available). It should also be used with ... including tubo-peritoneal infertility, intrauterine synechiae, chronic endometritis. Urology: treatment of chronic prostatitis ... Longidase and Refortan for Correction of the Functional Activity of Peritoneal Macrophages in Acute Pancreatitis]. Актуальные ...
It more rarely arises in the vagina and fallopian tubes as well as primary pelvic or peritoneal sites, such as the omentum, ... Malignant neoplasms arising in endometriosis: clinicopathological study of 14 cases. Clin Exp Obstet Gynecol. 2004;31(4):302-4 ... Ovarian adenosarcomas have a worse prognosis than uterine adenosarcomas, presumably because of the greater ease of peritoneal ...
The patient died due to infected bile leakage into the peritoneal cavity. A German surgeon named Otto Sprengel reported the ... Gore RM, Shelhamer RP (October 2007). "Biliary tract neoplasms: diagnosis and staging". Cancer Imaging. 7 Spec No A (Special ...
Survival rates are higher when the cancer is more limited to lymph nodes, pleura, or peritoneal metastasis, which ranges from ... The remaining 10 percent are either poorly or undifferentiated malignant neoplasms (5%), or squamous cell carcinomas (5%). ...
Finally, c-myc gene expression is relatively high in neoplasms, and it is often linked to poor prognosis. Bilateral ... with a particular concern for rates of recurrence and peritoneal carcinomatosis.[citation needed] Chemotherapy regimens ...
... peritoneal cancer - peritoneal infusion - peritoneal perfusion - pernicious anemia - pertuzumab - PET scan - petechiae - Peutz- ... neoplasm - nephrotomogram - nephrotoxic - nephroureterectomy - nerve block - nerve grafting - nerve-sparing radical ... primary peritoneal cancer - primary tumor - primitive neuroectodermal tumor - prinomastat - pro-oxidant - probenecid - ... continuous hyperthermic peritoneal perfusion - continuous infusion - contralateral - control animal - control group - ...
The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms. Annals of surgical oncology. 2020 ... The Chicago Consensus on Peritoneal Surface Malignancies : Management of Ovarian Neoplasms. In: Annals of surgical oncology. ... The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms. / Chicago Consensus Working Group. ... Dive into the research topics of The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms. ...
Latin-American Clinical Care Center for Peritoneal Neoplasms. Latin-American Clinical Care Center for Peritoneal Neoplasms, a ... attaining in October 2015 the certification as a Clinical Care Center for the treatment of patients with Peritoneal Neoplasms ... Our patients involved any patient, from Colombia and other Latin-American countries, with peritoneal carcinomatosis. They are ...
ClinicalTrials.gov: Ovarian Neoplasms (National Institutes of Health) * ClinicalTrials.gov: Peritoneal Neoplasms (National ... Ovarian Cancer and Primary Peritoneal Cancer (PPC) (Foundation for Womens Cancer) * Ovarian, Fallopian Tube, and Peritoneal ... Primary peritoneal cancer forms in the tissue lining the peritoneum. Your peritoneum is a tissue lining that covers the organs ... General Information about Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (National Cancer Institute) Also in Spanish ...
Ovarian Neoplasms / surgery * Paclitaxel / administration & dosage* * Paclitaxel / adverse effects * Peritoneal Neoplasms / ... Methods: We randomly assigned patients with stage III ovarian carcinoma or primary peritoneal carcinoma with no residual mass ...
"Peritoneal Dissemination Complicating Morcellation of Uterine Mesenchymal Neoplasms". PLOS ONE. 7 (11): e50058. Bibcode: ...
Peritoneal Neoplasms/mortality, Postoperative Complications, Young Adult. in Journal of Surgical Oncology. volume. 109. issue. ... Peritoneal Neoplasms/mortality; Postoperative Complications; Young Adult}}, language = {{eng}}, number = {{6}}, pages = {{32-- ... The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer : a comparative ... BACKGROUND: Oxaliplatin and Mitomycin C (MMC) are both suitable as intraperitoneal chemotherapy agents in HIPEC for peritoneal ...
Primary Peritoneal Cavity Cancer. *Recurrent Ovarian Epithelial Cancer. *Peritoneal Neoplasms. *Neoplasms, Glandular and ... recurrent or persistent epithelial ovarian or primary peritoneal carcinoma receiving. Gleevec.. II. To determine the frequency ... Histologically confirmed ovarian epithelial or primary peritoneal carcinoma. - Recurrent or persistent disease. - At least 1 ... In The Treatment Of Persistent Or Recurrent Epithelial Ovarian Or Primary Peritoneal Carcinoma. Trial Phase:. Phase 2. Minimum ...
Peritoneal neoplasia can originate de novo from the peritoneal tissues (primary) or invade or metastasize into the peritoneum ... Pickhardt PJ, Bhalla S. Primary neoplasms of peritoneal and sub-peritoneal origin: CT findings. Radiographics. 2005 Jul-Aug. 25 ... encoded search term (Peritoneal Cancer) and Peritoneal Cancer What to Read Next on Medscape ... Peritoneal Cancer Guidelines. Updated: Feb 05, 2021 * Author: Wissam Bleibel, MD; Chief Editor: N Joseph Espat, MD, MS, FACS ...
Peritoneal neoplasms. en. dc.subject. Appendiceal neoplasms. en. dc.subject. Hyperthermic intraperitoneal chemotherapy. en. ... Background: Peritoneal carcinomatosis (PC) arising from the appendix is a rare disease with a poor long-term prognosis. The aim ...
... intraperitoneal chemotherapy following cytoreductive surgery for appendiceal mucinous neoplasms with isolated peritoneal ... Goblet cell carcinoid neoplasm of the appendix: clinical and CT features.﻽. Lee KS, Tang LH, Shia J, Paty PB, Weiser MR, ...
Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms. PLOS One. 2012;7(11):e50058. ... Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms. PLOS One. 2012;7(11):e50058. ... 18-20 Most leiomyosarcomas are Stage I, 21 but if the sarcoma tissue is open power morcellated in the peritoneal cavity, bits ... This practice permits small bits of tissue to spread around the peritoneal cavity ( FIGURE). Given the enhanced growth ...
Peritoneal Neoplasms 1 Thematic area. * Uruguay (Nacional) 24 * Cancer Prevention and Control (National) 2 ...
Sears D, Hajdu SI. The cytologic diagnosis of malignant neoplasms in pleural and peritoneal effusions. Acta Cytol. 1987;31:85- ... In rare cases, NK lymphoma may present as a peritoneal or pleural effusion.[70] The neoplasm characteristically involves the ... Chronic peritoneal dialysis has been associated with peritoneal fluid eosinophilia.[9] Other various causes reported in the ... Peritoneal fluid. Many of the hematologic malignancies presenting as peritoneal effusions can also manifest as pleural or even ...
RR for peritoneal neoplasm continued to increase by latency, duration and time since cessation of exposure. RR for lung cancer ... It also suggested a reduction in risk for pleural mesothelioma with over 40 years of latency, while risk for peritoneal ... and peritoneal (52 vs 1.9; p,0.01) malignancies and lung cancer (249 vs 103.1; p,0.01). In women, ovarian (9 vs 4.0; p,0.05) ... the RR of death from pleural neoplasm linearly increased with duration of exposure, while it showed a curvilinear increase with ...
Outcomes of Low-Grade Appendiceal Mucinous Neoplasms with Remote Acellular Mucinous Peritoneal Deposits.. Ann Surg Oncol. 2019 ... Analysis of Treatment Failure after Complete Cytoreductive Surgery for Peritoneal Metastasis from Appendiceal Mucinous Neoplasm ... BACKGROUND: Occasionally, low-grade appendiceal mucinous neoplasms (LAMN) present with mucinous peritoneal deposits (MPD) ... The sites of recurrence were peritoneal-only (n = 34, 69%), hematogenous-only (n = 6, 12%), and combined peritoneal and ...
Ki67 does not predict recurrence for low-grade appendiceal mucinous neoplasms with peritoneal dissemination after cytoreductive ... She is an expert in the treatment of peritoneal surface malignancies and other cancers that may have spread to the peritoneal ... She is an expert in the treatment of peritoneal surface malignancies and other cancers that may have spread to the peritoneal ...
Stomach Neoplasms. *Practice Guidelines as Topic. *Physicians. *Peritoneal Neoplasms. *Oncology & Carcinogenesis. * ... The Chicago Consensus on Peritoneal Surface Malignancies: Management of Gastric Metastases.. Publication , Journal Article ... The Chicago Consensus on Peritoneal Surface Malignancies: Management of Gastric Metastases. Ann Surg Oncol. 2020 Jun;27(6):1768 ... The Chicago Consensus on Peritoneal Surface Malignancies: Management of Gastric Metastases. Ann Surg Oncol. 2020 Jun;27(6):1768 ...
... stomach neoplasms/ or exp *liver neoplasms/ or exp *pancreatic neoplasms/ or exp *peritoneal neoplasms/ or exp *eye neoplasms/ ... pancreatic neoplasms/ or exp *peritoneal neoplasms/ or exp *hematologic neoplasms/ or exp *thoracic neoplasms/ or exp *bone ... cecal neoplasms/ or exp *duodenal neoplasms/ or exp *ileal neoplasms/ or exp *jejunal neoplasms/ or exp *stomach neoplasms/ or ... pc or exp COLONIC NEOPLASMS/pc or exp SIGMOID NEOPLASMS/pc or exp RECTAL NEOPLASMS/pc or exp ANUS NEOPLASMS/pc or exp NEOPLASMS ...
... may be a driving force in the field-effect theory for the development of both ovarian neoplasms and their associated peritoneal ... When ovarian neoplasms are encountered in girls of this age group, they fall into the germ cell, epithelial cell, and stromal/ ... Epithelial cystic tumors account for about 60% of all true ovarian neoplasms. One third of all ovarian tumors are serous, and ... 5] Fibromas are the most common benign ovarian neoplasms. These tumors occur most commonly in women of postmenopausal age. They ...
Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination ( ... a Adjusted for Peritoneal Cancer Index group and American Society of Anesthesiology. ... Sugarbaker PH: Management of peritoneal-surface malignancy: The surgeons role. Langenbecks Arch Surg. 384:576-487. 1999. View ... surgery was performed by gynecological surgeons and patient tumor burden was assessed according to the Peritoneal Cancer Index ...
ClinicalTrials.gov: Peritoneal Neoplasms By ACA , August 31, 2022. Need Caregiver Certification? Get that through the American ...
Patients with gynecologic tumors, urologic neoplasms, and/or peritoneal seeding may have developed ICEMs from direct tumor ... Cauda equina syndrome caused by primary and metastatic neoplasms. Neurosurg Focus 16(6): e3, 2004. PMID: 15202873. DOI: 10.3171 ... Metastatic peritoneal seeding was found in 1 patient with anal carcinoma (52) and 1 patient with ovary adenocarcinoma (7). ... some aggressive neoplasms may have different metastatic mechanisms responsible for synchronous ICEMs, as reported in 12 of our ...
Peritoneal Neoplasms Medicine & Life Sciences 61% * Cholangiocarcinoma Medicine & Life Sciences 53% * Gallbladder Medicine & ... Background: Hepatopancreaticobiliary malignancies with peritoneal carcinomatosis exhibit poor survival with current therapies: ... N2 - Background: Hepatopancreaticobiliary malignancies with peritoneal carcinomatosis exhibit poor survival with current ... AB - Background: Hepatopancreaticobiliary malignancies with peritoneal carcinomatosis exhibit poor survival with current ...
These neoplasms very rarely present with peritoneal implants or signs of microinvasion (defined as the presence of single or ... Peritoneal biopsies were performed in 27 women (49%), peritoneal cytology in 29 cases (53%) and positive in only 2 (7%). ... These neoplasms can be divided in two subtypes:. *. APTSs, Atypical proliferative serous tumors, behave in a benign way and ... They represent the 70% of BOTs, and 9-15% of all serous neoplasms [11,12] the mean age at presentation is 38 years old (range ...
Influence of fibre length, dissolution and biopersistence on the production of mesothelioma in the rat peritoneal cavity. ... cavities results in a preponderance of sarcomatous neoplasms, and in fact, it may be difficult to find mesothelial cells in ... 1984) The pathogenic effects of fibrous ceramic aluminum silicate glass administered to rats by inhalation or peritoneal ... In contrast to inhalation, direct instillation into the pleural or peritoneal ...
Chemotherapy administration into peritoneal cavity via indwelling port or catheter. CPT codes not covered for indications ... Malignant neoplasm of the liver, not specified as primary or secondary. C78.7. Secondary malignant neoplasm of liver and ... Malignant neoplasm of colon. C47.0 - C47.9, C49.0 - C49.9. Malignant neoplasm of connective tissue and other soft tissue [ ... Malignant neoplasm of the liver and intrahepatic bile ducts. C47.0 - C47.9, C49.0 - C49.9. Malignant neoplasm of connective ...
The aim of this study was to explore the correlation between serum CA125, peritoneal cancer index, and intra-operative mapping ... Conclusion We found that pre-operative CA125 ,600 U/mL, peritoneal cancer index ,20, and intra-operative mapping of ovarian ... Pre-operative serum CA125, peritoneal cancer index and intra-operative mapping score as predictors of surgical results in ... Pre-operative serum CA125, peritoneal cancer index and intra-operative mapping score as predictors of surgical results in ...
keywords = "consensus, mesothelioma, neoplasm metastasis, peritoneal neoplasms",. author = "{Chicago Consensus Working Group} ... The Chicago Consensus on peritoneal surface malignancies: Management of peritoneal mesothelioma. Cancer. 2020 Jun 1;126(11): ... The Chicago Consensus on peritoneal surface malignancies : Management of peritoneal mesothelioma. In: Cancer. 2020 ; Vol. 126, ... The Chicago Consensus on peritoneal surface malignancies: Management of peritoneal mesothelioma. Chicago Consensus Working ...
Neoplasms. D009369. C80. 1. -. -. -. -. 1. Peritoneal neoplasms. D010534. 1. -. -. -. -. 1. Renal cell carcinoma. D002292. 1. - ...
Germ Cell and EmbryonalPalatal NeoplasmsDigestive System NeoplasmsPeritoneal NeoplasmsNeoplasms, Complex and MixedPelvic ... Pancreatic NeoplasmsNeoplasmsLymphatic MetastasisSkin NeoplasmsNeoplasms, Cystic, Mucinous, and SerousLung NeoplasmsNeoplasms, ... Cord NeoplasmsVaginal NeoplasmsAdrenal Gland NeoplasmsNervous System NeoplasmsPenile NeoplasmsNeoplasm SeedingGenital Neoplasms ... Uterine NeoplasmsBreast NeoplasmsColonic NeoplasmsBone Marrow NeoplasmsEndocrine Gland NeoplasmsIntestinal NeoplasmsNeoplasms, ...
  • Our patients involved any patient, from Colombia and other Latin-American countries, with peritoneal carcinomatosis. (vbhcprize.com)
  • BACKGROUND: Oxaliplatin and Mitomycin C (MMC) are both suitable as intraperitoneal chemotherapy agents in HIPEC for peritoneal carcinomatosis (PC) of colorectal cancer (CRC). (lu.se)
  • Background: Peritoneal carcinomatosis (PC) arising from the appendix is a rare disease with a poor long-term prognosis. (umontreal.ca)
  • Background: Hepatopancreaticobiliary malignancies with peritoneal carcinomatosis exhibit poor survival with current therapies: hepatocellular carcinoma 11 months with sorafenib, and pancreaticobiliary 9-14 months with systemic chemotherapy. (mssm.edu)
  • Methods: We retrospectively reviewed our institutional hepatopancreaticobiliary malignancies with peritoneal carcinomatosis which underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy from 2007 to 2017 and analyzed perioperative and oncologic outcomes. (mssm.edu)
  • Conclusions: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy may offer a survival benefit in select hepatocellular carcinoma patients with peritoneal carcinomatosis, though has dubious utility in pancreaticobiliary malignancies. (mssm.edu)
  • 0.001), mostly presenting as invasive peritoneal carcinomatosis. (uni-luebeck.de)
  • Conclusion: Positive cytology does not directly predict peritoneal carcinomatosis and, while associated with advanced disease, does not contraindicate radical surgery. (elsevierpure.com)
  • Peritoneal carcinomatosis and peritoneal sarcomatosis is a potential complication of nearly all solid tumors and results in profoundly increased morbidity and mortality. (elsevierpure.com)
  • Despite the ubiquity of peritoneal carcinomatosis/peritoneal sarcomatosis, there are no clinically relevant targeted therapies for either its treatment or prevention. (elsevierpure.com)
  • To identify potential therapies, we developed in vitro models of peritoneal carcinomatosis/peritoneal sarcomatosis using tumor cell lines and patient-derived spheroids (PDS) that recapitulate anoikis resistance and spheroid proliferation across multiple cancer types. (elsevierpure.com)
  • Implications: Development of BNIP3/BNIP3L-targeting agents or autophagy-targeting agents may reduce morbidity and mortality associated with peritoneal carcinomatosis and sarcomatosis. (elsevierpure.com)
  • Six immunizations of LAK cells generated in media containing fetal calf serum abrogated the ability of mice to respond to IL-2 plus LAK immunotherapy in a peritoneal carcinomatosis model. (prinsesmaximacentrum.nl)
  • Chicago Consensus Working Group 2020, ' The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms ', Annals of surgical oncology , vol. 27, no. 6, pp. 1780-1787. (northwestern.edu)
  • [ 28 ] ERAS notes that cytoreductive surgery, with or without the addition of hyperthermic intraperitoneal chemotherapy, (CRS ± HIPEC) has become a treatment standard for peritoneal surface malignancies. (medscape.com)
  • Promoting Awareness of PMP (Pseudomyxoma Peritonei), Appendiceal Cancer and other Peritoneal Surface Malignancies. (cancerindex.org)
  • A charitable organization founded in 2008 by a community of individuals affected by Pseudomyxoma Peritonei (PMP) and related Peritoneal Surface Malignancies (PSM). (cancerindex.org)
  • She is an expert in the treatment of peritoneal surface malignancies and other cancers that may have spread to the peritoneal lining, including the use of advanced therapies such as cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). (utah.edu)
  • Scholars@Duke publication: The Chicago Consensus on Peritoneal Surface Malignancies: Management of Gastric Metastases. (duke.edu)
  • Chicago Consensus Working Group 2020, ' The Chicago Consensus on peritoneal surface malignancies: Management of peritoneal mesothelioma ', Cancer , vol. 126, no. 11, pp. 2547-2552. (elsevierpure.com)
  • Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms . (lookformedical.com)
  • In cytomorphological analyses, the presence of clusters with ragged edges and isolated carcinoma cells can be considered to indicate a high risk of peritoneal recurrence. (elsevierpure.com)
  • The most common histology-high-grade serous epithelial ovarian cancer-is considered as a single clinical entity along with fallopian tube and peritoneal cancers because of shared clinical features. (msdmanuals.com)
  • Additionally, in contrast to pleural mesothelioma, which has a male predominance (male-female ratio of between four and five to one), women comprise approximately one-half of all cases of malignant peritoneal mesothelioma. (karger.com)
  • Malignant peritoneal mesothelioma (MPM) is a highly lethal malignancy of the serosal membranes of the pleura, peritoneum, pericardium, or tunica vaginalis testes. (karger.com)
  • The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of ovarian neoplasms specifically related to the management of peritoneal surface malignancy. (northwestern.edu)
  • It also suggested a reduction in risk for pleural mesothelioma with over 40 years of latency, while risk for peritoneal mesothelioma showed a continuing increase. (bmj.com)
  • The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of peritoneal mesothelioma. (elsevierpure.com)
  • A peritoneal mesothelioma affecting mainly young females and producing cysts of variable size and number lined by a single layer of benign mesothelial cells. (bvsalud.org)
  • Peritoneal mesothelioma accounts for 10-15% of cases.Most patients with malignant pleural mesothelioma present late in the course of their disease, with an asymptomatic early process. (standardofcare.com)
  • Primary Peritoneal Mesothelioma is a rapidly aggressive and rare neoplasm that arises from the lining of mesothelial cells of the peritoneum and spreads extensively within the confines of the abdominal cavity. (karger.com)
  • Characteristically, asbestos exposure has a strong relationship with mesothelioma of the pleura, but the peritoneal cavity is the second most commonly affected site. (karger.com)
  • Only 10-15% of the approximately 3,300 cases of mesothelioma diagnosed in the USA every year are peritoneal, resulting in about 600 new cases annually, making this a rare occurrence [1]. (karger.com)
  • Methods: We searched medical and pathology records and specimens for 127 workers from a textile-asbestos factory in Italy who died during 1963-2013 with a diagnosis of pleural or peritoneal neoplasm or mesothelioma on death certificate, to confirm the diagnosis with immunohistochemistry markers. (unimi.it)
  • Epithelial cystic tumors account for about 60% of all true ovarian neoplasms. (medscape.com)
  • Mucinous epithelial tumors account for approximately 10-15% of all epithelial ovarian neoplasms. (medscape.com)
  • Thus, type I (low-grade serous G1, low-grade endometrioid G1/G2, mucinous or clear cell) tumors are associated with corresponding benign ovarian cystic neoplasms, often developing through an intermediate borderline step and have a better prognosis. (spandidos-publications.com)
  • Unexpected malignant tumors are a rare finding after surgery for symptomatic leiomyomas but there is little doubt that morcellation of these lesions is associated with a higher risk of iatrogenic peritoneal spread compared to women having surgery without morcellation [ 2 ]. (oncotarget.com)
  • Diaphragmatic Peritoneal Stripping Versus Full-Thickness Resection in CRS/HIPEC: Is There a Difference? (mssm.edu)
  • Dive into the research topics of 'Diaphragmatic Peritoneal Stripping Versus Full-Thickness Resection in CRS/HIPEC: Is There a Difference? (mssm.edu)
  • CONCLUSIONS: Analyses by time-dependent variables showed that the risk for pleural neoplasms increased with latency and no longer increases at long TSFE, consistent with with asbestos clearance from the lungs. (bvsalud.org)
  • Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. (lookformedical.com)
  • Excluding one patient with atypical cells, positive cytology results were obtained in 19 patients (14 per cent): 16 patients without macroscopic peritoneal metastases (group 2) and three patients with minimal macroscopic peritoneal metastases (group 3). (elsevierpure.com)
  • Primary peritoneal cancer forms in the tissue lining the peritoneum. (medlineplus.gov)
  • Peritoneal cancer index, number of organs resected, completeness of cytoreduction, and 30-day morbidity were equivalent. (mssm.edu)
  • Objective To investigate whether neoadjuvant chemotherapy followed by interval debulking surgery is superior to primary debulking surgery in terms of perioperative complications and progression-free survival, in advanced epithelial ovarian, fallopian tube or primary peritoneal cancer patients with high tumor load. (bmj.com)
  • Methods Patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer (stage IIIC-IV) underwent laparoscopy. (bmj.com)
  • Background: The aim of this study was to assess the implications of positive peritoneal washing cytology for management of patients with potentially resectable pancreatic cancer. (elsevierpure.com)
  • Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. (lookformedical.com)
  • Peritoneal stomata constitute the principal pathways for the drainage of intraperitoneal contents from the PERITONEAL CAVITY to the LYMPHATIC SYSTEM. (bvsalud.org)
  • Multiple peritoneal parasitic myomas after laparoscopic myomectomy and morcellation. (mdedge.com)
  • Takeda A, Mori M, Sakai K, Misui T, Nakamura H. Parasitic peritoneal leiomyomatosis diagnosed 6 years after laparoscopic myomectomy with electric tissue morcellation: Report of a case and review of the literature. (mdedge.com)
  • check the tag ADOLESCENCE HN - 2008 BX - Nutrition in Adolescence FX - Adolescent Nutrition Physiology MH - Peritoneal Stomata UI - D054048 MN - A01.047.025.600.700 MN - A10.810 MS - Natural openings in the subdiaphragmatic lymphatic plexus in the PERITONEUM, delimited by adjacent mesothelial cells. (bvsalud.org)
  • These, through a highly specialized team, advanced surgical techniques and state of the art technology attaining in October 2015 the certification as a Clinical Care Center for the treatment of patients with Peritoneal Neoplasms by the Joint Commission International and the recertification in 2018 for the continuous compliance with quality standards. (vbhcprize.com)
  • The purpose of our study was to develop modern epidemiological data for adult patients completing an appendectomy for UA secondary to an appendiceal neoplasm (AN). (cancerindex.org)
  • However, relapses usually remain BOT in the preserved ovaries as opposed to older patients being at higher risk for malignant transformation in peritoneal or distant localisation. (uni-luebeck.de)
  • Methods: Cytological examination of peritoneal washings was performed in 134 patients who underwent surgical resection for pancreatic adenocarcinoma. (elsevierpure.com)
  • The neoplasms may be histologically the same or different, and may be found in the same or different sites. (lookformedical.com)
  • 28 and 47 months later, respectively, the patient presented with peritoneal spreading of nodules that were surgically removed and histologically classified as leiomyosarcoma. (oncotarget.com)
  • Inclusion criteria: Histologically proven primary high risk leiomyosarcoma (LMS) or Liposarcoma (LPS) of retroperitoneal space or infra-peritoneal spaces of pelvis. (who.int)
  • Arises primarily from the surface of serosal cells of the pleural, peritoneal and pericardial cavities and is a highly aggressive neoplasm. (standardofcare.com)
  • This Clinical Policy Bulletin addresses treatment approaches for liver and other neoplasms. (aetna.com)
  • Percutaneous ethanol injection (PEI) for liver neoplasms when criteria above are not met. (aetna.com)
  • Perioperative Systemic Chemotherapy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: Results of the Prospective Multicenter Phase 2 COMBATAC Trial. (medscape.com)
  • Progression-free survival in selected patients with colorectal or appendiceal peritoneal metastasis might be improved. (medscape.com)
  • Tumor cell metastasis to the peritoneal cavity is observed in patients with tumors of peritoneal organs, particularly colon and ovarian tumors. (nih.gov)
  • This case confirms the aggressive behavior of PMA and makes clinicians aware of the possibility of extraneural, peritoneal metastasis through a VP shunt. (johnshopkins.edu)
  • Following release into the peritoneal cavity, tumor cells rapidly attach to the omentum, a tissue consisting of immune aggregates embedded in adipose tissue. (nih.gov)
  • We hypothesized that activation of the immune aggregates would generate a productive antitumor immune response in the peritoneal cavity. (nih.gov)
  • The nonspecific response was long-lived and not present systemically, highlighting the uniqueness of the peritoneal cavity. (nih.gov)
  • Collectively, these data demonstrate that the peritoneal cavity has a unique environment capable of eliciting potent specific and nonspecific antitumor immune responses. (nih.gov)
  • Diffuse involvement of the peritoneal cavity is typical, often including omental caking and diaphragmatic and pelvic tumor deposits. (medscape.com)
  • The excision resulted in inadvertent entry into the peritoneal cavity, resulting in luminal collapse. (sages.org)
  • The sensitivity of the test results depends on the ability to completely lavage all regions of the peritoneal cavity and to detect cancer cells being shed into the peritoneal cavity by the tumor. (medscape.com)
  • 2 ] Therefore, high-grade serous adenocarcinomas arising from the fallopian tube and elsewhere in the peritoneal cavity, together with most ovarian epithelial cancers, represent extrauterine adenocarcinomas of Müllerian epithelial origin and are staged and treated similarly to ovarian cancer. (gvortho.com)
  • In Peritoneum and Mesentery - part I: Anatomy the normal anatomy and physiology of the peritoneum and peritoneal cavity are discussed. (radiologyassistant.nl)
  • The management of peritoneal carcinoma is similar to that of epithelial cancers of ovarian and fallopian tube, due to similar clinical characteristics. (medscape.com)
  • Epithelial cancers of ovarian, fallopian tube, and peritoneal origin are known as epithelial ovarian cancer in clinical practice. (medscape.com)
  • High-grade serous epithelial ovarian carcinoma, fallopian tube carcinoma, and primary peritoneal carcinomas are thus considered a single clinical entity (i.e., epithelial ovarian cancer [EOC]) due to their shared pathologic behavior and treatment. (arkansasbluecross.com)
  • This PDQ summary addresses the staging and treatment of ovarian epithelial cancer, fallopian tube cancer (FTC), and primary peritoneal cancer (PPC). (gvortho.com)
  • The fimbriated ends of the fallopian tubes are in close apposition to the ovaries and in the peritoneal space, as opposed to the corpus uteri (body of the uterus) that is located under a layer of peritoneum. (gvortho.com)
  • Twenty-six patients with synchronous or metachronous colorectal or appendiceal peritoneal carcinomatosis were included. (medscape.com)
  • INTRODUCTION: Appendiceal neoplasms have a propensity for peritoneal dissemination. (bvsalud.org)
  • METHODS: This was a single-institution retrospective review of 164 cases of mucinous appendiceal neoplasm. (bvsalud.org)
  • Purpose: Peritoneal carcinomatosis from appendiceal goblet cell carcinoma (A-GCC) is a rare and aggressive form of appendiceal tumor. (tmu.edu.tw)
  • PSOGI Working Group & BIG-RENAPE Working Group 2022, ' An International Registry of Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy ', World Journal of Surgery , 卷 46, 編號 6, 頁 1336-1343. (tmu.edu.tw)
  • Mucinous appendiceal neoplasms and pseudomyxoma peritonei: Morphological and clinical findings, differential diagnosis, and prognosis. (nih.gov)
  • Atypical presentations of primary peritoneal carcinoma have been described, including a case of severe glandular dysplasia on a screening Papanicolaou test (Pap smear). (medscape.com)
  • Primary peritoneal carcinoma usually manifests as abdominal distention and diffuse nonspecific abdominal pain secondary to ascites. (medscape.com)
  • A pelvic imaging study, if there is clinical suspicion of peritoneal carcinoma. (medscape.com)
  • Five patients with advanced colorectal and gastric carcinoma with peritoneal deposits were treated by continuous weekdays intraperitoneal (i.p.) instillation of 5-fluorouracil (5-FU) 200 mg m-2 day-1 in a novel dialysate solution that ensures maximal exposure of peritoneal areas liable to bear tumours for 24 h. (ox.ac.uk)
  • However, microscopically, the peritoneal tumors have the architectural and cytologic features of carcinoma, are derived from gastrointestinal mucinous adenocarcinomas, and are associated with a significantly worse prognosis than cases of adenomucinosis. (nih.gov)
  • Patients with malignant peritoneal mesothelioma usually present with symptoms and signs of advanced disease, including pain, ascites, weight loss, or an abdominal mass. (medscape.com)
  • Pathological examination revealed a benign peritoneal tumor, which was diagnosed as a peritoneal inclusion cyst. (gynaecologyjournal.com)
  • Peritoneal inclusion cyst is a less common benign primary peritoneal tumor. (radiologyassistant.nl)
  • Peritoneal mesotheliomas: clinicopathologic features, CT findings, and differential diagnosis. (medscape.com)
  • This article reviews available literature with quantitative information on mesothelioma underascertainment, in particular on different rates of underestimation for pleural and peritoneal mesotheliomas, and suggests two approaches to estimating downward bias in absolute risk estimates due to mesothelioma underascertainment. (cdc.gov)
  • The choice of approach used depends on whether the information on the proportion of peritoneal mesotheliomas is available. (cdc.gov)
  • CT findings in patients with malignant peritoneal mesotheliomas range from peritoneum-based masses (a so-called "dry" appearance) to ascites, irregular or nodular peritoneal thickening, and an omental mass (a so-called "wet" appearance). (medscape.com)
  • Malignant mesotheliomas (MM) are neoplasms arising from mesothelial cells that line the body cavities, most commonly the pleural and peritoneal cavities. (mesothelioma-line.com)
  • BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) as parts of an interdisciplinary treatment concept including systemic chemotherapy can improve survival of selected patients with peritoneal metastatic colorectal cancer (pmCRC). (medscape.com)
  • Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. (medscape.com)
  • Background: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is effective in select patients with peritoneal carcinomatosis (PC). (mssm.edu)
  • Cytoreductive surgery (CRS) and hyperthermic intra peritoneal chemotherapy (HIPEC) was reported as an interesting alternative regarding survival compared to surgery without HIPEC and/or systemic chemotherapy. (tmu.edu.tw)
  • This collaborative work is the result of a gathering of some of the leaders in the field of intraperitoneal chemotherapy for ovarian cancer and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis at an international symposium held at the University of Louisville, Kentucky, in May 2005. (nshealth.ca)
  • This is a Phase II study for people age 18 and older who have been diagnosed with pleural or peritoneal malignant mesothelioma, have a measurable tumor with no brain metastases, have had no previous systemic chemotherapy and haven't had radiation therapy in the previous four weeks. (mesotheliomalaw.net)
  • pregnancy, acute pelvic inflammatory disease, marked cervical erosion, endocervicitis and intrauterine bleeding, in the immediate pre-or postmenstrual phase, within 30 days of curettage or conization or patients with known or suspected reproductive tract neoplasia due to the risk of peritoneal spread of neoplasm. (nih.gov)
  • Women with higher risk of ovarian cancer also have increased risk of peritoneal cancer. (medscape.com)
  • Tumors that have spread to the lining of the abdomen from other cancers, such as cancer of the appendix, colon, or ovary, are called peritoneal carcinomatosis. (nih.gov)
  • Surface epithelial-stromal tumors are a class of ovarian neoplasms that may be benign or malignant. (oujanime.org)
  • Peritoneal spread of gastrointestinal (GI) or gynecologic malignancies or primary peritoneal neoplasms is a significant problem for the practicing oncologist because of the poor prognosis associated with these entities and the debilitating effect they have on people who suffer from them. (icloudhospital.com)
  • These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. (elsevierpure.com)
  • An unusual extra-peritoneal abdominal neoplasm. (nih.gov)
  • Peritoneal cystic mesothelioma (BMPM) is a very rare benign cystic tumor arising from the peritoneal mesothelium (lining of the abdominal wall). (nih.gov)
  • Open abdominal exploration and palpation are extremely sensitive for 1- to 2-mm peritoneal nodules. (medscape.com)
  • Peritoneal carcinomas are divided into primary and secondary peritoneal tumors. (medscape.com)
  • Primary peritoneal carcinomas originate from the cells lining the peritoneum. (medscape.com)
  • Secondary peritoneal carcinomas usually invade locally or metastasize into the peritoneum from adjacent or remote organs. (medscape.com)
  • 1 ] In addition, histologically similar cancers diagnosed as primary peritoneal carcinomas share molecular findings, such as loss or inactivation of the tumor-suppressor p53 and BRCA1 or BRCA2 proteins. (gvortho.com)
  • Despite the ubiquity of peritoneal carcinomatosis/peritoneal sarcomatosis, there are no clinically relevant targeted therapies for either its treatment or prevention. (elsevierpure.com)
  • Benign multicystic mesothelioma and peritoneal inclusion cysts: are they the same clinical and histopathological entities? (nih.gov)
  • Peritoneal inclusion cysts are often confused with ovarian neoplasms because of their various appearances on imaging studies. (gynaecologyjournal.com)
  • This article incorporates text in the public domain from page 1256 of the 20th edition of Gray's Anatomy (1918), "Southern Illinois University School of Medicine", https://en.wikipedia.org/w/index.php?title=Stroma_of_ovary&oldid=963999021, Wikipedia articles incorporating text from the 20th edition of Gray's Anatomy (1918), Creative Commons Attribution-ShareAlike License, This page was last edited on 23 June 2020, at 00:46. (oujanime.org)
  • Peritoneal MMMT are frequently associated with gynecologic tumors. (elsevierpure.com)
  • Peritoneal mucinous carcinomatosis is characterized by abundant peritoneal mucinous tumor, similar to the clinical presentation of adenomucinosis. (nih.gov)
  • Pseudomyxoma peritonei is less common, but looks quite similar to peritoneal carcinomatosis. (radiologyassistant.nl)
  • Survival was followed, and the immunophenotype of cells in the peritoneal tumor microenvironment was evaluated. (nih.gov)
  • We will discuss the differential diagnosis of cystic and solid peritoneal and mesenteric masses. (radiologyassistant.nl)
  • Mucinous carcinomatosis is the most likely diagnosis of cystic peritoneal masses. (radiologyassistant.nl)
  • Two years later she presented with peritoneal carcinomatoses which was consistent with metastatic tumor via a ventriculoperitoneal (VP) shunt. (johnshopkins.edu)
  • Peritoneal tumors usually do not cause symptoms in the early stages of the diseases. (medscape.com)
  • abstract = "Peritoneal carcinomatosis and peritoneal sarcomatosis is a potential complication of nearly all solid tumors and results in profoundly increased morbidity and mortality. (elsevierpure.com)
  • Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. (lookformedical.com)
  • 9. ΔNp73 status in peritoneal and ovarian dissemination of appendicular adenocarcinoids (goblet cells). (nih.gov)
  • Peritoneal hemangiomas are usually associated with hemangiomas of the GI tract. (medscape.com)
  • Extensive clinical and pharmacological research investigations have been done, with exceptional therapeutic outcomes, propelling peritoneal surface oncology to the forefront of clinical oncology treatment and research. (icloudhospital.com)
  • Disseminated peritoneal adenomucinosis is characterized by copious mucinous ascites (the classical clinical syndrome of PMP) and histologically bland peritoneal mucinous tumors. (nih.gov)
  • A third group of tumors displays intermediate or discordant histologic features but manifests a clinical course very similar to cases of pure peritoneal carcinomatosis. (nih.gov)

No images available that match "peritoneal neoplasms"